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AbstractAll living creatures change their gene expression program in response tonutrient availability and metabolic demands. Nutrients and metabolites can directlycontrol transcription and activate second-­‐messenger systems. In bacteria,metabolites also affect post-­‐transcriptional regulatory mechanisms, but there areonly a few isolated examples of this regulation in eukaryotes. Here, I presentevidence that RNA-­‐binding by the stem cell translation regulator Musashi-­‐1 (MSI1)is allosterically inhibited by 18-­‐22 carbon ω-­‐9 monounsaturated fatty acids. Thefatty acid binds to the N-­‐terminal RNA Recognition Motif (RRM) and induces aconformational change that prevents RNA association. Musashi proteins are criticalfor development of the brain, blood, and epithelium. I identify stearoyl-­‐CoAdesaturase-­‐1 as a MSI1 target, revealing a feedback loop between ω-­‐9 fatty acidbiosynthesis and MSI1 activity. To my knowledge, this is the first example of anRNA-­‐binding protein directly regulated by fatty acid. This finding may represent oneof the first examples of a potentially broad network connecting metabolism withpost-­‐transcriptional regulation.
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1Chapter I: Introduction
2Musashi is an RNA-­‐binding protein essential for neural and epithelial
development
Stem cells have the capacity to replicate continually and differentiate intoalmost any cell type in the organism. Understanding the molecular mechanisms thatmaintain the pluripotent state of stem cells is essential to basic and pharmaceuticalresearch. Stem cell research goals include the design of strategies to distinguishdifferentiated from pluripotent cells, specific induction of stem cell differentiation,and the potential for reprogramming patient-­‐specific adult cells for research andtreatment.Regulation of gene expression at the translational level allows organisms tomodulate the production of protein frommRNA according to specific developmentalcues. Post-­‐transcriptional and post-­‐translational mechanisms enable organisms toregulate the expression of already-­‐transcribed genes. Post-­‐transcriptionalregulation takes many forms, including capping, poly-­‐A tail addition, splicing,translocation, mRNA stabilization or destabilization, sequestration, and editing.Some proteins, such as capping enzymes and splicing factors, act constitutively onmost RNAs, while other proteins target a more limited set of specific transcripts tomodulate gene expression according to precise cues. Understanding the
3mechanisms by which these specific RNA-­‐binding proteins recognize and regulateexpression of their targets is essential to understanding development.
Musashi family proteins protect stem and progenitor cell fateMusashi-­‐1 (MSI1) is a dual RNA Recognition Motif (RRM) RNA-­‐bindingprotein. MSI1 has a similar RNA binding domain to Drosophila melanogasterMusashi (Msi), which regulates asymmetric division of sensory organ precursorcells (Nakamura et al. 1994; Sakakibara et al. 1996). Msi was identified in a mutantfly with an external sensory bristle patterning defect (Nakamura et al. 1994;Sakakibara et al. 1996). Normal bristles consist of four cells: A neuron, a glial cell,and two external support cells called shaft and socket cells. In MSI mutant flies, theratio of these cells is aberrant, leading to a phenotype in which some bristles containmultiple shaft cells so they appear to have double bristles (Nakamura et al. 1994).Msi regulates this asymmetric division by participating in a regulatory feedbackloop with TTK69 and Notch (Okabe et al. 2001).Mouse Msi1 was identified by its homology to Msi and Xenopus laevisnervous system-­‐specific RNP protein-­‐1 (xNRP1), also known as xMsi1 (Sakakibaraet al. 1996). Human MSI1 (hMSI1) was later identified during the human genomeproject by its homology to Msi, xNRP1/xMsi, and mMsi1 (Good et al. 1998). Thevertebrate Msi1 proteins are highly expressed in central nervous system (CNS) stemcells and in progenitor cells that give rise to glia and neurons. Expression is lost indifferentiated glial and neuronal cells, suggesting that Msi1 plays a role in
4neurogenesis (Figure 1.1) (Sakakibara et al. 1996; Good et al. 1998). Although Msi1was first characterized in the nervous system, Msi1 is also expressed in epithelialstem and progenitor cells, where it promotes proliferation and preventsdifferentiation (Kayahara et al. 2003; Nishimura et al. 2003; Potten et al. 2003;Akasaka et al. 2005; Asai et al. 2005; Colitti and Farinacci 2009; Murayama et al.2009). The importance of Msi1 in the epithelial cell lineage was further confirmedwhen Lan et al. demonstrated that Msi1+ mouse embryonic stem cells have thecapacity to differentiate into neural and epithelial cells when hypodermicallyengrafted onto the backs of adult mice (Lan et al. 2010).Several other MSI family proteins have also been identified in vertebratesand flies. Musashi-­‐2 (Msi2) is 69% identical to Msi1 at the amino acid level and isexpressed primarily in hematopoietic and leukemic stem cells (Figure 1.2)(Sakakibara et al. 2002; Kharas et al. 2010; Park et al. 2014). Additionally, Msi2 isrequired for embryonic stem cell self-­‐renewal and pluripotency (Wuebben et al.2012; Park et al. 2014). Zebrafish have two main splice variants of the Musashi 1homolog (zMsi1) (Shibata et al. 2012). zMsi1 is expressed in neural tissue duringdevelopment, and knockdown of zMsi1 results in CNS abnormalities (Shibata et al.2012). Although Msi was the first MSI family protein identified in Drosophila
melanogaster, recent genome sequencing efforts have revealed that RBP6 sharesgreater sequence homology with mouse Msi1 and human MSI1 (Siddall et al. 2012).

6Figure 1.1: Pattern of MSI1 expression in the central nervous system. Blue cellsindicate MSI1 expression pattern.

8Figure 1.2: MSI1 and MSI2 are highly conserved. Sequence alignment shows 69%conservation between MSI1 and MSI2 across the entire protein, and 83%conservation within the RRM domains. Regions that correspond to α-­‐helices, β-­‐sheets, and intervening loops as defined by NMR spectroscopy for MSI1 RRM1 arediagramed above the alignment.
9While RBP6 does not share Msi functionality in regulating asymmetric division ofneural stem cells, it does appear to be expressed along with Msi in mouse germlinecells (Siddall et al. 2012; Sutherland et al. 2013). A growing body of evidencesuggests that MSI family proteins are involved in stem cell maintenance anddifferentiation, but little is yet known about the mechanisms by which MSI proteinsregulate these processes.In 2001, the Okano lab used in vitro SELEX experiments to identify aptamersthat bind to Msi1 (Imai et al. 2001). The Msi1 consensus sequence, (G/A)U1-­‐3AGU,was identified by eye in most SELEX aptamers (Imai et al. 2001). Msi1 RRM1 bindsto RNA with greater affinity than RRM2, which is thought to stabilize the RNAinteraction (Imai et al. 2001; Miyanoiri et al. 2003). NMR studies indicate that RRM1is more dynamic than RRM2, possibly explaining the difference in apparent RNAaffinities by the two RRM domains (Miyanoiri et al. 2003). The Katahira lab recentlypublished the NMR structure of Msi1 RRM1 bound to the minimal motif GUAGU(Ohyama et al. 2011). The RNA-­‐bound structure reveals that specific MSI1 residuesinteract with the RNA bases (Figure 1.3). As expected, most of the residues thatinteract with RNA are located on the beta sheet face, but some residues in theflexible loop regions also associate with RNA. Notably, the adenine (position 3) andguanine (position 4) bases stack with two of the three conserved phenylalaninesfound on the beta sheet face of most RRM domains, but the adenine is sandwichedby a third phenylalanine (F96) from a loop region. Additionally, the first guaninestacks on a tryptophan (W29) in the loop between β1 and α1 (Ohyama et al. 2011).

11
Figure 1.3: RNA-­‐bound NMR structure of Msi1 RRM1 bound to RNA. Adapted fromOyahama et al, 2011.
12
Thermodynamic characterization of RNA mutants by Ruth Zearfoss has sincerevealed that sequence recognition by Msi1 is primarily driven by the presence of aUAG element (Zearfoss et al., submitted). This recent understanding of the MSIexpression pattern and consensus binding sequence will be useful in the study ofMSI family function in a number of systems, including gametogenesis,neurodevelopment, and cancers of the neural and epithelial lineages.
Musashi-­‐1 in gametogenesis and embryogenesisGametogenesis is a precise cell cycling and differentiation process thatresults in the formation of a haploid gamete. During gametogenesis, gametesundergo periods of transcriptional inactivation, during which they must maintaintemporal and spatial expression of genes required for proper development.Sequence-­‐specific RNA-­‐binding proteins assist in the translational control of mRNAtranscripts that have been produced and stored in the gametes prior totranscriptional inactivation. Members of the Musashi family of RNA-­‐bindingproteins have been identified in germ cells of several organisms, where they assistin regulating the expression of genes critical for developmental.
Xenopus laevisMusashi (xMsi) expression in the reproductive system islocalized to the oocyte, where it plays a critical role in oocyte maturation(Charlesworth et al. 2006). Polyadenylation assays show that xMsi1 translationallyactivates the proto-­‐oncogeneMos, an essential regulatory factor in oocytematuration. xMsi1 binds to theMos 3ʹ′ UTR and associates with the poly-­‐A
13
polymerase Germline Development-­‐2 (GLD2) to promote cytoplasmicpolyadenylation and translation (Charlesworth et al. 2006; Prasad et al. 2008;Cragle and Macnicol 2014). Interestingly, MSI-­‐dependent Mos activation still occursif xMsi1 is replaced by mouse Msi1 in Xenopus oocytes, indicating functionalconservation across species (MacNicol et al. 2011).MSI proteins are also crucial to meiotic progression during Xenopusgametogenesis (Gunter and McLaughlin 2011). Antisense ablation of both xMsi1 andxMsi2 in embryos halts meiotic progression and germinal vesicle breakdown(GVBD). Knockdown of either xMsi1 or xMsi2 yields a less-­‐dramatic phenotype, withdelayed GVBD and slower meiotic progression (Gunter and McLaughlin 2011).MSI regulation during gametogenesis and embryogenesis in other systemshas not been studied as comprehensively. Recent proteomics experiments indicatethat MSI protein expression in oocytes is conserved among vertebrates andinvertebrates (Lotan, et al. 2014). In mice, in situ hybridization andimmunohistochemical analysis reveals that MSI proteins are expressed in the sertolicells of the testis and the granulosa cells of the ovaries (Saunders et al. 2002). In
Drosophila testis, loss of MSI disrupts the balance between germline stem cellrenewal and differentiation, resulting in the premature differentiation (Siddall et al.2006). Finally, there is evidence that the association between MSI proteins andGLD2 is conserved in mammals, which indicates that the mechanism of translationalactivation described in Xenopus oocytes may be widespread, although this has notyet been tested (Cragle and Macnicol 2014).
14
Musashi-­‐1 is essential for neural developmentNeural development relies on a complex series of temporal and spatial cuesthat enable precise differentiation of neural stem cells into highly specializedmature cells of the central and peripheral nervous system. These cells mustaccurately sense and relay information about the organism and its environment. Inthe central nervous system (CNS), which consists of the brain and spinal cord,oligodendrocytes form a myelin sheath by wrapping long cellular processes aroundneuronal axons (Figure 1.4). Myelin is an essential structure in the vertebratenervous system that protects against neural degeneration and enables saltatorynerve impulse propagation. Oligodendrocyte maturation is a tightly regulatedprocess. To become myelin-­‐producing oligodendrocytes, progenitor cells mustundergo a specific program of proliferation, migration, and differentiation, but weare still far from understanding the how these processes are regulated.In the forebrain, oligodendrocyte progenitor cells originate from a neuralstem cell population maintained in the subventricular zone (SVZ) (Levison andGoldman 1993). Mitogens and chemo-­‐attractants such as platelet-­‐derived growthfactor (PDGF) and fibroblast growth factor-­‐2 (FGF-­‐2) promote oligodendrocyteprogenitor cell proliferation and migration throughout the CNS (Li et al. 2009).When oligodendrocyte progenitor cells reach their target, signals in the localenvironment trigger differentiation (Li et al. 2009).

16
Figure 1.4: Schematic representation of an oligodendrocyte forming a myelin layerto wrap around a neuronal axon (left), and a cutout representation of the layeredcomposition of the myelin membrane (right) (Adapted from Zearfoss, et al. 2008).
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Regulation of the decision to proliferate or differentiate is likely complicatedby the highly polarized nature of oligodendrocyte progenitor cells. These cells mustsense changes in the extracellular environment and quickly respond by alteringgene expression in regions far from the cell body. Post-­‐transcriptional regulatorymechanisms allow cells to swiftly and regionally respond to environmental stimuli.It is therefore not surprising that several RNA binding proteins, including Quaking,Fragile X Mental Retardation Protein and MSI1, have been implicated in regulatingoligodendrocyte differentiation and myelination (Ebersole et al. 1996; Wang et al.2004). Msi1 is an essential regulatory factor involved in central nervous systemdevelopment, as demonstrated through a variety of in vivo and cell-­‐based assays(Sakakibara et al. 2002; Dobson et al. 2008). Quantitative analysis of mousehippocampal gene expression patterns indicates that increased Msi1 expression iscorrelated with increased neural stem cell proliferation (Yagita et al. 2001).Additionally, Msi1 positive embryonic stem cells hypodermically engrafted intomice differentiate into a variety of tissue types, including epithelial and neural-­‐likecells (Lan et al. 2010). Interestingly, MSI family involvement in neurodevelopment ishighly conserved, with supporting data in Planaria, Drosophila, C. elegans, and allvertebrates assessed to date (Higuchi et al. 2008; MacNicol et al. 2008).Msi1 null mice are born alive but die within 1-­‐2 months of birth (Sakakibaraet al. 2002). These mice display ataxia and hydrocephaly, a swelling of the brain.
18
Additionally, their brains are underdeveloped, and they have a pronouncedexpansion of progenitor cells from the ependymal layer of the neural tube.Embryonic neurospheres isolated from these mice contain fewer cellular lineages(Sakakibara et al. 2002).In normal mice, imaging studies indicate that Msi1 is expressed in neural andglial progenitor cells, but not in mature neurons or glia (Figure 1.1) (Kaneko et al.2000; Dobson et al. 2008). Msi1 knockdown in primary mouse oligodendrocyteprogenitor cells results in increased caspase-­‐3 production and apoptosis (Dobson etal. 2008). Elevated Msi1 expression in primary mouse oligodendrocyte progenitorcells blocks differentiation into mature oligodendrocytes (Dobson et al. 2008). Myown unpublished data demonstrate that MSI1 reduction induces immortalizedoligodendrocyte precursor cells to differentiate (Figure 1.5). Together, the Msi1knockout mouse phenotypic and cell-­‐based experiments indicate that Msi1regulates neural progenitor and stem cell fate.To date, only a few Msi1 targets have been identified and validated in neuraltissue. The NOTCH antagonist NUMB was the first Msi1 target identified invertebrates. Msi1 associates with consensus elements in the Numb 3′ UTR in vitro,and NumbmRNA co-­‐immunoprecipitates with Msi1 protein from NIH 3T3 cells thathave been transiently transfected with a HAT-­‐tagged Msi1 construct. Finally, Msi1negatively regulates luciferase protein expression from a reporter constructharboring the Numb 3′ UTR.
19
Figure 1.5
Control siRNA 10nM
Msi1siRNA 10nM Msi1siRNA 10nM
Control siRNA 10nM
20
Figure 1.5: Msi1 knockdown induces differentiation in CG-­‐4 OPCs. DIC (left) orfluorescent (right) images of CG-­‐4 cells transfected with non-­‐targeting controlsiRNA (top panels) or siRNA targeting Msi1 (bottom panels).
21
Reporter mRNA levels remain unaffected by Msi1 expression, indicating that Msi1negatively regulates NUMB translation (Imai et al. 2001). NUMB inhibition isthought to be accomplished through a mechanism where the Msi1 C-­‐terminus bindspoly(A) binding protein, competing with eIF4G and preventing 80s ribosomeassembly (Kawahara et al. 2008). NF-­‐YA, a transcription factor that activatestranscription of a Notch subunit, has also recently been identified as a putative Msi1target (Lagadec et al. 2014). More work is needed to characterize the nature andextent of NF-­‐YA regulation by Msi1.MSI1 also translationally represses transcripts encoding the cell cyclingantagonist p21WAF-­‐1 (Battelli et al. 2006). Transient transfection of a Msi1 expressionvector in HEK293T cells reduces p21WAF-­‐1 protein levels but does not affect mRNAlevels. Gel shift assays show that Msi1 interacts with a Msi1 binding site in thep21WAF-­‐1 3′ UTR (Battelli et al. 2006). Additionally, Msi1 negatively regulatesexpression of a p21WAF-­‐1 3′ UTR dsRED reporter in HEK293T cells (Battelli et al.2006). More recently, several putative Msi1 targets have been identified but notstudied to the extent of NUMB and p21WAF-­‐1. The immature neuronal migrationfactor doublecortin (DCX) has been identified as a MSI1 regulatory target (Horisawaet al. 2009). Msi1 binds to the 3′ UTR of DCX transcripts, and translationallyrepresses expression of a DCX luciferase reporter in Neuro2A cells (Horisawa et al.2009). Another putative Msi1 target is ROBO3, a protein involved in precerebellarneuron migration (Kuwako et al. 2010). Msi1 binds to ROBO3 transcripts and
22
upregulates ROBO3 protein levels in precerebellar neurons. Both Msi1 and ROBO3knockout mice display similar midline crossing defects (Kuwako et al. 2010). Msi1may also indirectly downregulate biogenesis of the microRNA let-­‐7, an antagonist ofstem cell proliferation (Kawahara et al. 2011). Together these Msi1 targets providea link between Msi1 and its observed role as a factor involved in neurodevelopmentand stem cell preservation.
Msi1 promotes cancerous tumor growthCancerous tumors often contain stem-­‐ and progenitor-­‐like cells in which theproliferation checks and balances have malfunctioned. Proliferation-­‐associatedfactors are increased in these cancers, while cell cycle regulatory factors are oftendecreased. Some of these factors are termed oncogenes for their apparent role instimulating cancerous tumor growth. MSI1 was initially used as a common markerfor neural and epithelial stem and progenitor cells, but recent evidence indicatesthat MSI expression is also elevated in cancerous tumors (Johnson et al. 2010; Levinet al. 2010). It is therefore not surprising that MSI1 has recently become a researchfocus as factor that likely supports tumorigenesis.MSI1 is currently used as a marker of colorectal adenocarcinoma,medulloblastoma, ependymoma, endometrial carcinoma, esophagealadenocarcinoma, and oral squamous carcinoma (Nakano et al. 2007; Schulenburg etal. 2007; Gotte et al. 2008; Bobryshev et al. 2010; Ravindran and Devaraj 2012). RIP-­‐ChIP analysis of MSI1-­‐associated transcripts from HEK293T cells reveals 64 novel
23
putative regulatory targets (de Sousa Abreu et al. 2009). Of these, most are involvedin cancer-­‐related processes such as cell cycling, proliferation, differentiation, andapoptosis. Subsequent proteomics analysis indicates that these putative Msi1targets undergo both positive and negative regulation in response to Msi1overexpression (de Sousa Abreu et al. 2009).A study with glioblastoma U87 tumor cell grafts showed that MSI1expression increased with each successive tumor generation, indicating possibletumor cell dedifferentiation (Strojnik et al. 2006). Similarly, MSI1 mRNA isexpressed at significantly higher levels in adenocarcinoma tissues than in normalcolorectal mucosa tissues (Fan et al. 2010). MSI1 is expressed in 68% of primarybreast tumors and in 100% of lymph node metastatic tumors that began as breasttumors (Wang et al. 2010).MSI1 depletion in medulloblastoma and colorectal tumors results indecreased proliferation and increased apoptosis (Sanchez-­‐Diaz et al. 2008; Surebanet al. 2008). MSI1 knockdown in MCF-­‐7 and T47D breast tumor cells reduces cellsurvival and tumor xenograft growth (Wang et al. 2010). Conversely,overexpression of MSI1 in intestinal progenitor cells results in activation of the Wntand Notch pathways and increased tumorigenesis in xenograph studies (Rezza et al.2010). MSI1 also activates Notch signaling in endometrial carcinoma, where it hasalso been shown to regulate its cell cycling target P21WAF1 (Gotte et al. 2011).A number of recent studies indicate that patient prognosis is correlated toMSI1 expression in tumors of neural and epithelial lineage. In patients with
24
malignant gliomas, poor prognosis is strongly correlated with MSI1 expressionlevels (Strojnik et al. 2007; Dahlrot et al. 2013). This correlation was also seen inpatients with medulloblastoma tumors (Vo et al. 2012b). MSI1 expression issignificantly higher in stage III adenocarcinoma tumors than in stage I-­‐II tumors(Fan et al. 2010). Similarly, MSI1 levels are higher in tumors of the intestine than innormal intestinal mucosa (Kuang et al. 2013). Finally, poor patient prognosis isoften correlated to the development of metastatic tumors. The frequency with whichMSI is expressed in breast tumor tissue jumps from 68% of primary tumors to100% of metastatic tumors assayed, providing compelling evidence for the linkbetween patient survival and MSI1 expression (Wang et al. 2010).MSI2 is primarily expressed in hematopoietic stem cells (HSCs), althoughsome expression in neural stem and progenitor cells has been documented (Kharaset al. 2010; Lan et al. 2010). MSI2 knockdown results in reduced proliferation andincreased apoptosis of HSCs in vivo (Kharas et al. 2010). Overexpression of humanMSI2 promotes HSC cell cycling and proliferation in a mouse model (Kharas et al.2010). MSI2 is highly expressed in myeloid leukemia cell models and depletionresults in decreased proliferation and increased apoptosis (Kharas et al. 2010). Msi2knockout mice survive up to a year but display defects in hematopoietic progenitorcell production that becomes more pronounced as they age (de Andres-­‐Aguayo et al.2011). Immature hematopoietic cells in these animals display increaseddifferentiation as well as decreased proliferation (de Andres-­‐Aguayo et al. 2011).
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As with MSI1-­‐expressing cancers, MSI2 expression levels are directlycorrelated with poor prognosis in myeloid and lymphoblastic leukemia patients(Kharas et al. 2010; Mu et al. 2013). Myeloid leukemia patients are classified intodisease phases according to the severity of their symptoms and bone marrowcomposition. Phases include the almost asymptomatic chronic phase, theaccelerated phase, and the blast crisis phase. Blast crisis behaves like an acuteleukemia, usually resulting in patient death. Intriguingly, the samples from patientsin blast crisis have low expression of the MSI1 target Numb (Ito et al. 2010). Loss ofMSI2 restores Numb expression and attenuates the blast crisis phase, renderingMSI2 an attractive drug target in the quest for leukemia therapies (Ito et al. 2010).
Taken together, this body of previous research indicates that MSI familyproteins may present a logical therapeutic target for various cancers andneurodegenerative diseases. However, regulation of MSI1 has not been extensivelystudied, so effective MSI1-­‐targeting therapies have not yet been developed. Whilethere is some correlation between expression of certain micro RNAs, post-­‐transcriptional regulatory factors, transcription factors, and cyclin-­‐dependent andmitogen-­‐activated protein kinases, more work is needed to determine whether theyregulate MSI1 activity (Vo et al. 2011; Arumugam et al. 2012; Vo et al. 2012a; Pastoet al. 2014). Interestingly, there is also evidence that MSI1, thyroid hormone, andthe microtubule-­‐associated protein tau are involved in a regulatory loop (Cuadradoet al. 2002). In Xenopus laevis, thyroid hormone administration induced xMsi1
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expression in adult intestinal progenitor cells, but not in differentiated epithelialcells (Ishizuya-­‐Oka et al. 2003). However, many of the mechanisms by which MSIproteins are regulated have not been established.
Metabolic regulation of gene expressionMetabolite homeostasis is required for normal cellular and systemic function,and the loss of homeostasis often leads to disease. A classic example is type Idiabetes, where a precipitous change in blood glucose levels, caused by a failure ininsulin signaling, leads to blindness, sores, infections on extremities, and nervedamage. To maintain homeostasis, organisms must sense and respond to changes inmetabolic state by altering gene expression. However, the many of the mechanismsgoverning metabolite-­‐mediated changes in gene expression remain a mystery.There are numerous examples of metabolites regulating transcription factoractivity (Wang et al. 1994; Kliewer et al. 1997). For example, the peroxisomeproliferator-­‐activated receptor (PPAR) family of nuclear hormone receptors binddirectly to fatty acids and eicosanoids. Upon metabolite association, PPARs bind tospecific DNA elements in promoters and act as transcription factors to regulateexpression of a variety of genes, including several involved in lipid metabolism(Wang et al. 1994; Kliewer et al. 1997; Berger and Moller 2002). A number ofpotent synthetic PPAR ligands are used to treat diseases such as dyslipidemia anddiabetes. In fact, metabolite responsive transcription factors are targeted in severaltherapeutic strategies, probably because of their importance in regulating gene
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expression and their ability to bind to small molecule metabolite ligands (Zeng andXie 2011).Second messenger signaling also couples metabolic state to gene expression.Metabolites, hormones, gasses, and other small molecules bind and activatereceptors on the cell surface to enact an intracellular signaling cascade that leads tothe activation or repression of specific genes. An example of second-­‐messengersignaling is the phosphoinositide 3-­‐kinase (PI3K) pathway. PI3K catalyzes theformation of inositol trisphosphate (IP3) in response to a number of hormones andmetabolites involved in cell growth and survival (Alcazar-­‐Roman andWente 2008;Kim et al. 2011). IP3 regulates genes involved in cell cycling and apoptosis via themammalian target of rapamycin (mTOR) pathway (Kim et al. 2011). These complexsignaling cascades have received extensive attention because activating or inhibitingmetabolite and hormone surface receptors using small molecules can be atherapeutic strategy.While bacteria widely use mechanisms of metabolic post-­‐transcriptionalregulation, there are relatively few examples in eukaryotes. Here, I will review somewell-­‐know bacterial metabolite sensors, as well as the few eukaryotic examplesdescribed to date.
Riboswitches: metabolite-­‐sensitive RNA elementsRiboswitches are structured RNA elements often found in the 5′ untranslatedregion (UTR) of bacterial transcripts. They sense the concentration of specific
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metabolites through direct interactions. Metabolite binding typically induces achange in riboswitch conformation that in turn alters transcription termination ortranslation initiation efficiency. As such, riboswitches provide a negative feedbackloop that shuts down production of metabolic enzymes and related factors requiredto produce the associated metabolite.The first riboswitch was described in 2002 by Breaker and coworkers, whoreported that in Escherichia coli, transcripts of the cobalamin (vitamin B12)biosynthesis operon btuB directly bind cobalamin to induce a structural change thatprevents ribosome binding (Nahvi et al. 2002). Since then, many riboswitches havebeen identified and categorized into classes based upon the type of ligand and thesecondary structure formed upon association with that ligand. To date more than 20classes of riboswitches sensitive to a variety of metabolites have been identified inbacteria. In contrast, only one class of riboswitch has been discovered in eukaryotes.A number of excellent reviews on bacterial riboswitches have been publishedrecently (Winkler and Breaker 2005; Roth and Breaker 2009; Breaker 2012).
TPP Riboswitches in EukaryotesThe thiamine-­‐responsive TPP riboswitch is the most common bacterialriboswitch, and it has now been identified in plants, fungi, and archaea (Figure 1.6)(Kubodera et al. 2003; Cheah et al. 2007; Croft et al. 2007; Bocobza and Aharoni2008). Hanamoto et al. discovered the first eukaryotic TPP riboswitch in the 5′ UTR
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Figure 1.6: TPP-­‐regulated alternative splicing of the NMT1 gene. A) Schematic of the5' UTR intron structure. The thin line above the schematic denotes the predominantisoform in low TPP conditions. The thick line below the schematic denotes thepattern in high TPP conditions. B) The low TPP isoform contains a short 5' UTR witha single initiation codon, leading to efficient translation of NMT1. C) The high TPPisoform contains a longer 5' UTR with two uORFs, leading to reduced translationinitiation of the cognate NMT1 ORF. D) Chemical structure of TPP, sensed by theriboswitch motif in the 5' UTR intron.
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of the thiA gene of the filamentous fungus Aspergillus orzyae, used in the productionof sake (Kubodera et al. 2003). An intron is present in the thiA 5′ UTR that containstwo motifs highly conserved in fungal thiamine biosynthesis genes. Reporter studiesand northern analyses revealed that thiamine concentration controls the extent of 5′intron splicing in a manner that depended on both conserved elements. Theincrease in unspliced 5′ UTR mRNA in the presence of thiamine correlates with adecrease in the expression of thiA. Subsequent studies by Breaker et al. identifiedsequences that match a TPP riboswitch consensus descriptor in thiaminebiosynthesis genes from Arabidopsis thaliana, Oriza sativa (rice), Poa secunda(bluegrass), and the fungi Neurospora crassa and Fusarium oxysporum (Sudarsan etal. 2003). Structural probing revealed that the element from Arabidopsis, found inthe thiA 3′ UTR, adopts a TPP riboswitch-­‐like structure in the presence of thiamine,suggesting that the element comprises a bona fide riboswitch similar to thoseobserved in bacteria.In the case of the TPP riboswitch from the Neurospora crassa NMT1 5′ UTR(Figure 1.6), the riboswitch induces alternative splicing (Cheah et al. 2007). In thepresence of elevated TPP, an upstream 5′-­‐splice site is used leading to production ofan mRNA with a longer 5′ UTR. The TPP riboswitch motif is present within theintron sequence that is normally spliced out. The longer mRNA includes anupstream open reading frame (uORF) that decreases translation of the downstreamgene product by competing with the authentic translation start site. The data reveal
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a mechanism whereby a structural change in the TPP riboswitch repressestranslation of the NMT1 gene via a change in the splice isoform ratio.Additional studies of eukaryotic TPP riboswitches reveal a common role inmodulating alternative mRNA splicing as a means of regulating gene expression(Thore et al. 2006; Croft et al. 2007; Thore et al. 2008). It is intriguing to note thatthe eukaryotic riboswitches work by modifying a eukaryote-­‐specific process thatoccurs in the nucleus, rather than affecting transcription or translation initiationdirectly, as in bacteria. Although several examples of the TTP riboswitch have beencharacterized in eukaryotes, other riboswitch classes have not yet been identified.It is possible that they do not exist; however, it is likely that through refinement ofbioinformatics and experimental techniques, additional examples will be found.
Identifying eukaryotic riboswitchesA number of groups have used riboswitch sequence and structureconservation to search bacterial genomes for additional riboswitches (Vitreschak etal. 2003; Abreu-­‐Goodger et al. 2004; Barrick et al. 2004; Weinberg et al. 2007; Meyeret al. 2008). Merino and colleagues published an algorithm that sorted and pairedoperons with Clusters of Orthologous Groups (COGs) from the protein database(Abreu-­‐Goodger et al. 2004; Abreu-­‐Goodger and Merino 2005). Next they usedsuccessive rounds of Multiple EM for Motif Elicitation (MEME) followed by MotifAlignment and Search Tool (MAST) to identify over-­‐represented motifs in each COG(Abreu-­‐Goodger et al. 2004; Bailey et al. 2009). A subsequent publication described
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the development of RibEx (riboswitch explorer), a tool that cross-­‐references thegenomes of non-­‐redundant bacterial organisms to identify sequence motifs ofputative riboswitches and other structural regulatory elements (Abreu-­‐Goodger etal. 2004; Abreu-­‐Goodger and Merino 2005). RibEx eliminates the use of COGs infavor of using 145 complete genomes in the initial alignment. Unfortunately, asimilar tool does not yet exist for eukaryotes.Riboswitch identification in eukaryotes has proven challenging due to theincreased complexity of the regulatory mechanisms governing gene expression. Inbacteria, riboswitch aptamer domains have high sequence conservation, whileexpression platforms can have disparate sequence, and the regulatory mechanismsare often inferred by their location. These expression platforms are usuallypositioned to block ribosome binding sites or prevent formation of transcriptionterminating stems. Identifying eukaryotic riboswitch expression platforms iscomplicated by a number of factors. First, eukaryotic genes are not grouped intooperons. Second, riboswitches could theoretically work at the level of mRNAprocessing, nuclear export, stability, or translation. Eukaryotic riboswitches aretherefore likely to have a heterogeneous nature at the structural and sequencelevels. Third, most prokaryotic genomes are roughly 88% protein-­‐coding, whilehigher organisms such as humans are estimated to have as little as 2% protein-­‐coding sequence (Dinger et al. 2011). The increased size and complexity ofeukaryotic genomes presents both challenges and possibilities forbioinformaticians. The large number of mRNA processing events identified in
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eukaryotes, combined with the possibility that riboswitches may exist in non-­‐codingRNAs to regulate gene expression in trans leads to almost limitless possibilities foreukaryotic riboswitch mechanisms. It is therefore not surprising that bioinformaticsapproaches have been difficult to develop for eukaryotic riboswitch identification.Several groups have begun to search for non-­‐coding RNAs within intergenicsequences of bacteria, archea, and eukaryotes. Although these searches are notspecifically targeting riboswitch identification, it is possible that the methodologyand the precedent set by this type of bioinformatic search may influence futureriboswitch discovery in organisms other than bacteria. Breaker and colleagues havebeen optimizing clustering techniques to discover novel non-­‐coding RNAs inbacteria (Weinberg et al. 2009). Similarly, a recent bioinformatic survey of thearchaean Pyrococcus abyssi used clustering of sequence, primary structure, andsecondary structure to identify conserved non-­‐coding RNAs located in intergenicregions. This study revealed several elements that share features with the SAM-­‐Iand lysine bacterial riboswitches, although this remains to be experimentally tested(Phok et al. 2011). Although most recent work has focused on ribozyme discovery,the recent success in identifying large non-­‐coding RNAs may enable futureapplication of similar methods to the discovery of non-­‐coding RNAs, includingriboswitches, in eukaryotes.Because only one riboswitch class has been identified in eukaryotes, it is notclear whether eukaryotic riboswitches are rare, or have not been discovered due tothe increased complexity of higher organisms. If higher organisms truly lack of
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riboswitches, perhaps proteins have taken over metabolite-­‐sensing functionality.Numerous proteins regulate gene expression at the post-­‐transcriptional level, and ahandful of canonical RNA-­‐binding proteins have demonstrated metabolitesensitivity. Additionally, over the past two decades several metabolic enzymes havedemonstrated RNA-­‐binding activity.
Metabolite-­‐sensitive RNA-­‐binding proteinsRNA-­‐binding proteins alter gene expression by regulating pre-­‐mRNA processingsteps including alternative splicing, 5′ and 3′ end formation, and by controlling howthe RNA sequence is edited. RNA binding proteins also regulate the subcellularlocation, stability, and translation efficiency of mature mRNAs. Recent work hasshown that the activities of several RNA binding proteins are affected by theconcentration of cellular metabolites, allowing cells to quickly respond to changes inthe environment.
Introduction to ADARThe increased complexity of higher organisms cannot be explained by therelatively small increase in the number of protein-­‐coding genes relative to bacteria.Instead, genetic diversity can be attributed to an expansion in the number of geneproducts derived from each gene. Alternative pre-­‐mRNA splicing and mRNA editingenable recoding of the information stored in the genome leading to production ofmultiple protein variants from a single gene.
36
One example of mRNA editing is the programmed conversion of selectadenosine bases to inosine, catalyzed by enzymes termed adenosine deaminasesthat act on RNA (ADAR). ADARs were initially discovered in Xenopus laevis(Barraud and Allain 2012). Homologs have since been identified in most metazoa,but not in plants, fungi, or yeast (Barraud and Allain 2012). ADARs from differentorganisms are structurally similar; all contain several double-­‐stranded RNA bindingdomains (dsRBDs) and a highly conserved C-­‐terminal deaminase domain. ADARsdeaminate specific adenosines to produce inosine at precise locations within anRNA sequence. Inosine pairs with cytidine and is therefore interpreted as a guaninebase in biological settings. These editing events cause single-­‐codon alterations,changes in alternative splicing, and modulation of mRNA stability (Farajollahi andMaas 2010).RNA editing has been observed in pre-­‐mRNA coding sequences, repetitiveelements, and pri-­‐miRNAs (Farajollahi and Maas 2010). Neurons use editingextensively to regulate specialized neurotransmitter receptors, ion channels, andsurface protein isoforms (Maas et al. 2006). Mice stably expressing an shRNA thatsilences ADAR2 expression display increased neuronal sensitivity to restrictedblood and nutrient supply and subsequent neuronal degeneration (Peng et al.2006). ADAR activity is also reported to affect subcellular compartmentalization ofcertain mRNAs, and self-­‐editing of ADAR mRNA is proposed to affect ADAR homo-­‐and hetero-­‐dimerization which in turn regulates mRNA editing efficiency (Rueter etal. 1999; Palladino et al. 2000; Sansam et al. 2003; Valente and Nishikura 2007;
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Maas and Gommans 2009). ADAR editing is implicated in a number of disease statesincluding schizophrenia, neuromuscular disorders, and certain cancers (Schmauss2005; Maas et al. 2006; Peng et al. 2006).The Bass group determined the high-­‐resolution crystal structure of thecatalytic domain of ADAR2 and discovered an inositol hexakisphosphate (IP6)molecule required for proper folding of the enzyme (Macbeth et al. 2005) (Figure1.7). Subsequent experiments showed that an ADAR substrate is edited in wild typeyeast expressing hADAR2, but not in yeast that lack the IPK1 gene and thus do notproduce IP6 (Macbeth et al. 2005). The crystal structure revealed that IP6 isintimately associated with the protein, buried in an internal cavity lined with basicresidues. IP6 was not added during purification or crystallization, indicating thatendogenous IP6 co-­‐purified with the protein from yeast (Macbeth et al. 2005). Thissuggests that the association between ADAR and IP6 is likely very tight, although todate the dissociation constant has not been measured.It is probable that ADAR biogenesis is governed by intracellular IP6concentration (Alcazar-­‐Roman andWente 2008). IP6 is abundant in healthy cells,where it is involved in signaling pathways including proliferation, differentiation,DNA repair, energy transduction, and RNA export (Kalam Shamsuddin and Bose2012). IP6 serves as a phosphate donor in many signaling pathways. It is possiblethat IP6 levels influence the amount and stability of ADAR available to modifyspecific genes. This intriguing hypothesis requires additional biochemical and in
vivo studies, especially in light of data that suggests that loss of ADAR editing
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Figure 1.7: The structure of human ADAR2 bound to IP6. A) The surface of hADAR2is rendered in mesh, revealing the deep internal cavity that coordinates IP6(rendered in spheres). The structure was rendered from coordinate file 1ZY738. B)Chemical structure of IP6, sensed by ADAR.
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activity can lead to cancer, while abundant IP6 can help prevent cancers (Maas et al.2006; Kalam Shamsuddin and Bose 2012). Measurement of the extent of mRNAediting in the presence and absence of IP6, and determining the effect of editing oncellular physiology, will be necessary first steps towards demonstrating that ADARis a biologically relevant sensor of IP6 concentration.
Metabolic enzymes with RNA-­‐binding activityMetabolic enzymes are integral to maintaining homeostasis because theycatalyze the chemical reactions necessary to produce or use nutrients. Metabolicenzymes must be tightly regulated through feedback loops to ensure appropriatemetabolic flux. Some metabolic enzymes have been reported to ‘moonlight’ as RNA-­‐binding proteins, regulating gene expression at the post-­‐transcriptional level inaddition to catalyzing chemical reactions (Hentze and Preiss 2010). Hentze andPreiss termed this interplay between RNA, Enzymes and Metabolites the ‘REM’phase of RNA regulation (Hentze and Preiss 2010). The following sections willintroduce several examples of metabolic enzymes that act as RNA-­‐binding proteins,and discuss the possibility that the REM network may be more extensive than iscurrently realized.
Cytosolic aconitaseIron is an essential metabolite involved in processes including oxygentransport, cellular respiration and heme synthesis. Iron is also a cofactor for
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numerous metalloenzymes involved in a wide range of biological processes. Failureto regulate intracellular iron levels results in iron deficiency or toxicity. Free ironcatalyzes free radical generation, which can damage DNA, lipids, and proteins.Therefore, most intracellular iron exists in complex with enzymes and carrierproteins. Cytosolic aconitase is an iron-­‐sensitive enzyme that conditionally doublesas an RNA-­‐binding protein to regulate iron homeostasis (Klausner et al. 1993;Hentze and Kuhn 1996; Eisenstein 2000; Schneider and Leibold 2000; Theil andEisenstein 2000; Cairo et al. 2002; Rouault 2002). Interestingly, the functionality ofcytosolic aconitase in metabolic regulation was not understood until the discoverythat iron-­‐responsive protein-­‐1 (IRP1) and cytosolic aconitase are the same proteinwith two distinct functions.Aconitase is a tricarboxylic acid (TCA) cycle isomerase that catalyzes theconversion of citrate to isocitrate. Cytosolic aconitase (IRP1) has similar activity tothat of mitochondrial aconitase. It was initially unclear why cells would contain twodistinct copies of a functionally similar enzyme (Klausner and Rouault 1993). Whenintracellular iron is low, IRP1 binds iron-­‐responsive RNA elements (IREs) in ironregulatory genes to modulate their expression. The iron regulatory genes includethe iron storage factor ferritin, iron uptake factors like TfR and DMT-­‐1, and the ironexport factor ferroportin (Theil and Eisenstein 2000). When IRP1 was purified,sequenced, and cloned, it was found to have approximately 30% homology to
Saccharomyces cerevisiae and porcine mitochondrial aconitase (Rouault et al. 1989;Neupert et al. 1990; Rouault et al. 1990; Hentze and Argos 1991; Rouault et al. 1991;
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Hirling et al. 1992). Subsequent work showed that human recombinant IRP1 hasaconitase activity in the presence of iron, and bovine cytosolic aconitase binds toIREs in low iron conditions (Kaptain et al. 1991; Haile et al. 1992; Kennedy et al.1992). Further experiments from the Hentze and Klausner groups confirmed thatcytosolic aconitase and IRP1 are the same protein, with distinct functional activitiesdepending upon intracellular iron concentrations.In the presence of high intracellular iron the 4Fe-­‐4S catalytic clusterassembles to enable aconitase functionality (Dupuy et al. 2006). When intracellulariron decreases, the protein undergoes an allosteric change to reveal an ironresponsive element (IRE)-­‐binding site, enabling functionality as the RNA-­‐bindingprotein IRP1 (Figure 1.8) (Walden et al. 2006). The IRE is a highly conserved hairpinpresent in the 3′ and 5′ UTRs of several genes related to iron homeostasis(Henderson et al. 1994). Interaction between IREs and IRP1 induces repression offerritin mRNA translation and transferritin receptor mRNA stabilization (Butt et al.1996). How important is iron concentration sensing by IRP1? Interestingly, IRP1-­‐/-­‐mice develop normally without an apparent phenotype (Meyron-­‐Holtz et al. 2004).In contrast, IRP2-­‐/-­‐ mice display microcytic anemia, increased red cellprotoporphyrin IX levels, and neurodegeneration, but are otherwise normal(LaVaute et al. 2001; Cooperman et al. 2005). While mice that lack IRP1 or IRP2 areviable, mice that lack both fail in embryogenesis prior to implantation (Smith et al.2006). The mouse mutants reveal IRP activity is required for animal viability,
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Figure 1.8: The two forms of IRP1. A) structure of IRP1 in the iron replete stateadopts the canonical aconite fold. The protein structure is rendered as a cartoon, the4Fe-­‐FS cluster is rendered as spheres. The structure was rendered form coordinatefile 2B3X58. B) In iron deficient state, IRP1 adopts an alternative conformation thatbinds to a specific stem loop RNA structure (red). The structure was rendered fromcoordinate file 3SNP59. C) Chemical structure of the 4Fe-­‐4S cluster sensed by IRP1.
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highlighting the importance of regulating iron homeostasis at the post-­‐transcriptional level. They also suggest that IRP2 can compensate for loss of IRP1,while IRP1 is not sufficient to compensate for loss of IRP2 (Smith et al. 2006).Additional work is needed to understand the basis for this difference.
GAPDHGAPDH has traditionally been labeled a housekeeping protein because it isinvolved in glycolysis. However, several studies indicate that its biological activity ismore diverse (Sirover 1999; Nicholls et al. 2012). GAPDH has been shown to bind arange of RNA species, including mRNA, tRNA, rRNA and viral RNA, and mayparticipate in such activities as RNA export and regulation of RNA stability(Ryazanov 1985; Singh and Green 1993; Dollenmaier and Weitz 2003). GAPDHdirectly associates with AU-­‐rich elements (AREs) present in the 3′ UTRs of numberof RNA species (Nagy and Rigby 1995). In most cases, however, the physiologicalrelevance of RNA-­‐binding activity by GAPDH has not been validated.One proposed role for GAPDH RNA-­‐binding activity lies in the regulation ofcytokine and endothelin expression. Cytokines and endothelins are small bioactiveproteins that modulate the immune response and affect blood vessel constriction,respectively. GAPDH stabilizes mRNA encoding colony-­‐stimulating factor 1 (CSF1),which is implicated in tumorigenesis (Lin et al. 2001). Conversely, GAPDHassociation promotes turnover of transcripts encoding the endothelialvasoconstrictor endothelin (ET) (Rodriguez-­‐Pascual et al. 2008). The mechanism of
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GAPDH-­‐mediated regulation of mRNA stability is not known. There is growingevidence that GAPDH regulates lymphokine translation by binding lymphokinetranscripts in polysomes (Nagy and Rigby 1995). Again, the mechanism ofregulation is not known.In vivo, GAPDH is predicted to exist in two conformations: an RNA-­‐bindingform that is not active in glycolysis, and an NAD+-­‐binding form that is active inglycolysis (Nagy et al. 2000). The ratio of the two conformations may be regulatedby the local concentration of NAD+, NADH, and ATP (Nagy et al. 2000; Arutyunova etal. 2003). Oxidation state is also predicted to differentially affect the RNA-­‐ or NAD+-­‐binding activity of GAPDH (Nagy et al. 2000; Arutyunova et al. 2003). As such,GAPDHmay sense the concentration of oxidized NAD+ in order to controlexpression of mRNA targets. More work is needed to understand the mechanism bywhich GAPDH converts from an active metabolic enzyme to an RNA-­‐binding factor,and exactly how changes in metabolic state affect the various transcripts with whichit associates.
Identifying metabolite-­‐sensing proteins with RNA-­‐binding activityRecent advances in proteome-­‐wide assays are enabling rapid identification ofboth metabolite-­‐sensitive proteins with putative RNA-­‐binding activity and RNA-­‐binding proteins with putative metabolite-­‐sensing activity. Several techniques thatsurvey the RNA interactome and/or proteome can be used to assess changes uponalteration of metabolic state. These high-­‐throughput approaches, combined with
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experimental validation, may lead to identification of additional metabolite-­‐sensingRNA-­‐binding proteins.For proteins with known RNA-­‐binding activity, several methods are availableto identify associated transcripts in cells. These include HITS-­‐CLIP, PAR-­‐CLIP, andiCLIP, each of which rely on crosslinking of the protein to associated RNAs in cells,followed by immunoprecipitation and deep sequencing to identify the associatedRNA (Licatalosi et al. 2008; Hafner et al. 2010; Konig et al. 2011). To identify novelmRNA-­‐binding proteins, Hentze, Krijgsveld, and colleagues adapted the HITS-­‐CLIPand PAR-­‐CLIP methods to monitor the entire mRNA interactome (Castello et al.2012). In this technique, termed “interactome capture,” proteins are first cross-­‐linked to associated RNAs in cells. Next, cells are lysed and oligo d(T) beads are usedto capture polyadenylated RNA species. The protein interactome is then identifiedthrough mass spectrometry. In HeLa cells, over 300 novel RNA-­‐binding proteinswere identified by this approach, 46 of which are enzymes involved in intermediarymetabolism. This indicates that metabolic enzymes that also bind to RNA are morewidespread than previously thought. Because these enzymes function inintermediary metabolic pathways, they are logical candidates for couplingmetabolite sensing to RNA regulation.It will be more complicated to identify metabolite-­‐responsive RNA-­‐bindingproteins that are not established metabolic enzymes. It is possible that byemploying the methods outlined above while manipulating metaboliteconcentrations, some proteins will display altered RNA-­‐binding activity and/or
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target recognition. The most obvious candidates to use in this type of experimentare proteins that have already been shown to regulate genes involved in metabolitehomeostasis. Proteins demonstrating changes in RNA-­‐binding activity would thenrequire in vitro and in vivo experimentation to determine the mechanisms employedto sense and respond to metabolic state.In Chapter II, I outline a small molecule screen in which the intermediarymetabolite oleic acid was found to inhibit RNA-­‐binding activity of Msi1. Thissurprising result became the focus of my thesis research, in which I characterizedthe biochemical and biophysical nature of inhibition (Chapter II) and linked Msi1activity to lipid homeostasis and metabolism (Chapter III). I will present models toexplain the biological nature, mechanism, and consequences of fatty acid inhibitionof Msi1 in Chapters III and IV.
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Chapter II: The small molecule metabolite oleic acid is an allosteric
inhibitor of Musashi-­‐1 RNA-­‐binding activity
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AbstractStem and progenitor cells have the ability to differentiate into a wide variety ofspecialized cells and are often highly proliferative. These cells enable developmentin immature organisms, and cellular repair and regeneration in mature organisms.However, when the mechanisms governing progenitor cell proliferation fail,cancerous tumors form. In this chapter I present data for a small molecule screenand follow-­‐up experiments, in which I show that RNA-­‐binding by the stem celltranslation regulator Musashi-­‐1 (MSI1) is allosterically inhibited by 18-­‐22 carbon ω-­‐9 monounsaturated fatty acids. The fatty acid binds to the N-­‐terminal RNARecognition Motif (RRM) and induces a conformational change that prevents RNAassociation. Musashi proteins are critical for development of the brain, blood, andepithelium, and they are elevated in cancers of these lineages. MSI1 is therefore apromising therapeutic target in the ongoing search for cancer treatments.
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IntroductionThe RNA-­‐binding protein Musashi-­‐1 (MSI1) is expressed in stem andprogenitor cells of neural and epithelial lineage. In the central nervous system, MSI1is expressed in astrocytes and committed glial and neural progenitor cells, but not inmature neurons and oligodendrocytes (Figure 1.1) (Kaneko et al. 2000; Dobson etal. 2008). In histological studies of neural and epithelial tissues, MSI1 is routinelyused as a marker for stem and progenitor cells (Johnson et al. 2010). Analysis inmice and primary cells shows that Msi1 regulates neural development.Msi1-­‐/-­‐knockout mice are uncoordinated, ataxic, develop hydrocephaly, and die within 1-­‐2months after birth (Sakakibara et al. 2002). Their brains are small, contain anexpansion of early lineage progenitor cells, and display fewer mature cell types thannormal (Sakakibara et al. 2002). Embryonic neurospheres cultured fromMsi1-­‐/-­‐mouse brains have a reduced capacity to differentiate into mature neurons andoligodendrocytes (Sakakibara et al. 2002). In primary oligodendrocyte progenitorcells, Msi1 promotes progenitor cell survival and prevents differentiation intomature oligodendrocytes (Dobson et al. 2008). The phenotype and expressionpattern reveal that Msi1 plays an early role in regulating neurogenesis andgliogenesis.MSI1 contains two RRMs and is homologous to Drosophila melanogasterMusashi, a post-­‐transcriptional regulatory protein that guides external sensorybristle patterning in flies (Sakakibara et al. 1996). In vitro SELEX experimentsidentified a series of aptamer sequences that bind to Msi1 (Imai et al. 2001). Visual
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inspection identified a consensus sequence (G/A)U1-­‐3AGU that was present in mostbut not all of the aptamers. A number of Msi1 targets have been identified by co-­‐immunoprecipitation, including NUMB, a repressor of NOTCH signaling. Numbtranscripts harbor MSI1 consensus elements in the 3´ UTR (Imai et al. 2001). Msi1interacts with the Numb 3´ UTR in vitro, and NumbmRNA co-­‐immunoprecipitateswith MSI1 in transiently transfected NIH 3T3 cells. Overexpression of MSI1 in NIH3T3 cells decreases NUMB protein levels without affecting NumbmRNA and reducesthe expression of a luciferase reporter in a 3´ UTR dependent manner (Imai et al.2001). Together, the results show that MSI1 negatively regulates NumbmRNAtranslation. In contrast, xMsi1 acts as a translational activator in Xenopus laevisoocytes, where it modulates cell cycle progression by regulating mRNA encoding theproto-­‐oncogene Mos (Charlesworth et al. 2006).MSI1 also promotes proliferation of numerous cancers of the brain andepithelial tissues (Toda et al. 2001; Hemmati et al. 2003; Yokota et al. 2004;Sanchez-­‐Diaz et al. 2008; Sureban et al. 2008). MSI1 depletion in medulloblastomaand colorectal tumors results in decreased proliferation and increased apoptosis(Sanchez-­‐Diaz et al. 2008; Sureban et al. 2008). In colorectal tumors, MSI1 depletionis accompanied by inhibition of Notch-­‐1 and upregulation of p21WAF1, a MSI1 targetinvolved in cell cycle regulation (Battelli et al. 2006; Sureban et al. 2008). Musashi-­‐2(MSI2) is 69% identical to MSI1 protein and is expressed in a partially overlappingset of tissues (Figure 1.2) (Sakakibara et al. 2002). MSI2 regulates hematopoesis andis involved in acute myeloid leukemia (Ito et al. 2010; Kharas et al. 2010). In
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myeloid leukemia cells, MSI2 is highly expressed, and depletion results in decreasedproliferation and increased apoptosis (Kharas et al. 2010). The crisis phase ofmyeloid leukemia is marked by low NUMB expression (Ito et al. 2010). Loss of MSI2restores NUMB expression and impairs the blast crisis phase of myeloid leukemia(Ito et al. 2010). Ultimately, MSI2 expression levels are directly correlated with poorprognosis in myeloid leukemia patients (Kharas et al. 2010).Because of the importance of Musashi family proteins in stem and cancer cellproliferation, I sought to identify a small molecule inhibitor of MSI1 RNA-­‐bindingactivity. Four inhibitors were identified in a screen of more than 30,000 compounds,one of which is the intermediary metabolite oleic acid. Here I present data tocharacterize the specificity and mechanism of oleic acid inhibition.
Results
Small molecule screen to identify inhibitors of Musashi-­‐1To screen for small molecule inhibitors of MSI1 RNA-­‐binding activity, Ideveloped an in vitro assay pipeline amenable to high throughput measurements.First, I tested the ability of a purified, his6-­‐tagged Msi1 dual RRM construct (aminoacids 7-­‐192, Figure 2.1) to bind a fragment of a previously identified SELEX aptamer(CCCR005) (Imai et al. 2001) using two quantitative assays: fluorescenceelectrophoretic mobility shift (F-­‐EMSA) and fluorescence polarization (FP, Figure2.1) (Pagano et al. 2011). Msi1 binds with high affinity to the aptamer fragment,which contains two copies of the consensus sequence. Next, I optimized the FP assay
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Figure 2.1: His6-­‐Msi1 purification and activity test. (A) Coomassie-­‐stained SDS pagegel shows that recombinant MSI1 is purified to greater than 95% over a 3-­‐columnpurification protocol. (B-­‐D) EMSA and FP of MSI1 binding to RNA aptamer CCCR005(AGCGUUAGUUAUUUAGUUCG). EMSA data (red line) were fit to the Hill equationwhere all shifted species were fit as an aggregate. FP data (black line) were fit to atwo-­‐site binding model.
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for use in high throughput screens. This assay was used to screen two smallmolecule libraries: the 1280-­‐compound Sigma Library of Pharmacologically ActiveCompounds (LOPAC) and the 30,000-­‐compound Chembridge library (Figure 2.2A,Table 2.1A). Inhibitors identified in the screen were validated by dose responsemeasurements using both the FP and F-­‐EMSA assays (Figure 2.2).Four candidate inhibitors were identified. The weakest inhibitor was theChembridge compound 7409829 (Ki, app, FP = 15 ± 2.8 µM, Ki, app, F-­‐EMSA = 54 ± 22 µM).The most potent inhibitor was aurintricarboxylic acid (ATA, Ki, app, FP = 230 ± 30 nM,Ki, app, F-­‐EMSA = 1.55 ± 0.14 µM), a compound that readily polymerizes in aqueoussolution to form a polyanion. This compound has been identified in many highthroughput small molecule assays as a non-­‐specific inhibitor of protein-­‐nucleic acidinteractions (Lam et al. 1995). The next inhibitor was GW7647, a PPARα agonist(Berger and Moller 2002). PPARα is a nuclear hormone receptor that is activated bylong chain unsaturated fatty acids (Gottlicher et al. 1992; Bocos et al. 1995; Formanet al. 1997; Kliewer et al. 1997). The Ki, app for this compound was 6.5 ± 0.4 µM by FPand 21 ± 0.8 µM by F-­‐EMSA. The final inhibitor was oleic acid, an eighteen-­‐carbonmonounsaturated fatty acid with one double bond located nine carbons from thealiphatic—omega—end of the molecule (18:1, ω-­‐9). The apparent Ki of thiscompound was 1.2 ± 0.4 µM by FP and 1.4 ± 0.7 µM by F-­‐EMSA, and I observeddecreased affinity for the RNA aptamer with increasing concentrations of oleic acid(Figure 2.2 and 2.3A). The Ki, app is approximately two orders of magnitude below the
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Figure 2.2: Small molecule screen. (A) Assay scheme for the inhibitor screen and F-­‐EMSA dose responses with hits identified from the small molecule screens (A) andoleic and elaidic acid (B). Each gel is one representative experiment of at least threeindependent experiments. No compound and no protein lanes identify the positionof bound and free RNA migration, respectively.
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Table 2.1: Structure-­‐activity relationship analysis demonstrates specificity ofinhibition. (A) Small molecule screen hits. Compound ID (CID) refers to eachcompound’s LOPAC identification number. Screen scores were calculated bynormalizing the polarization value of each compound to the no protein and nocompound controls, as described in the supplemental methods. After the screen wascomplete, compounds that scored as hits were confirmed by FP and F-­‐EMSA doseresponse experiments. Apparent inhibition constants (Ki, app) are the average andstandard deviation of at least three independent experiments. (B) The code = carbonnumber : number of double bonds, followed by the position of the double bondsfrom the aliphatic end of the fatty acid. Where a fatty acid is modified, the parentalfatty acid numerical code is given in parentheses for comparison purposes. FP andF-­‐EMSA dose response results are reported as the average and standard deviation ofat least three independent experiments.
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Figure 2.3: Dissociation constant and CMC quantification. (A) Msi1 displaysdecreased affinity for an RNA aptamer upon addition of oleic acid. Apparentdissociation constants were determined by plotting fluorescence polarization as afunction of Msi1 protein concentration and fitting the data to the Hill equation. 0 µMoleic acid: Kd, app = 16.3 ± 1.2 nM; 1 µM oleic acid: Kd, app = 18.1 ± 2.6 nM; 10 µMoleic acid: Kd, app = 40.5 ± 3.5 nM; 0 µM oleic acid: Kd, app > 2000 nM. (B) CMCdetermination by N-­‐phenyl-­‐1-­‐naphthylamine (NPN) fluorescence in equilibrationbuffer (pH 8.0). Segmented linear regression was used to determine the breakpointbetween baseline and micelle-­‐associated NPN fluorescence. The value of the CMCpresented is the average and standard deviation from three experiments.
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critical micelle concentration (CMC) in equilibration buffer (pH 8.0) as measured byN-­‐phenyl-­‐1-­‐naphthylamine (CMC ≥ 75 ± 8 µM, Figure 2.3B).Oleic acid has been screened in 754 bioassays reported in the PubChemdatabase. Of these, oleic acid scored as positive in 4% of the assays. It should benoted that this figure overestimates the hit rate because it includes multiplebioassays that target the same protein. For example, oleic acid scored as a positivein eleven bioassays targeting fatty acid binding proteins (FABP) and seven assaysthat target membrane-­‐associated potassium channels. Both are known to besensitive to fatty acids (Capaldi et al. 2006; Boland and Drzewiecki 2008). Otherproteins responsive to oleic acid include fatty acid synthase, estrogen synthase,factor VIIa complex, and enterotoxin. It also scored positive in a screen formembrane permeant biomolecules. In total, only 14 unique proteins are responsiveto oleic acid. This suggests that oleic acid inhibition is specific.
Msi1 is specifically inhibited by 18-­‐22 carbon ω-­‐9 monounsaturated fatty acidsOleic acid is the most abundant fatty acid in body fat and is produced bymature oligodendrocytes during myelination (Martinez and Mougan 1998). Cellscan produce almost any fatty acid by modifying existing fatty acids throughmetabolic pathways. Because oleic acid is structurally related to a large number offatty acids, I obtained a library of fatty acids and analogs to assess the specificity ofinhibition (Figure 2.2B, Table 2.1). First, I measured inhibition by longer omega-­‐9
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monounsaturated fatty acids using the FP and F-­‐EMSA dose response assays.Eicosenoic acid (20:1, ω-­‐9) inhibited Msi1 with a potency similar to oleic acid (Ki, app,
FP = 1.2 ± 0.4 µM, Ki, app, F-­‐EMSA = 1.7 ± 0.6 µM). Erucic acid (22:1, ω-­‐9) was a strongerinhibitor (Ki, app, FP = 640 ± 150 nM, Ki, app, F-­‐EMSA = 820 ± 30 nM), and nervonic acid(24:1, ω-­‐9) inhibited more weakly (Ki, app, FP = 47 ± 25 µM, Ki, app, F-­‐EMSA = 23 ± 8 µM).Second, I assessed truncations and modifications of the aliphatic end of the fattyacid. Removing two carbons (palmitoleic acid, 16:1, ω-­‐7) had a moderate effect oninhibition (Ki, app, FP = 5.3 ± 0.5 µM, Ki, app, F-­‐EMSA = 12 ± 0.9 µM). The presence of ahydroxyl group at carbon 12 (ricinoleic acid, 12-­‐hydroxy-­‐oleic acid) had a strongereffect; inhibition is barely detectable by FP and reduced 15-­‐fold in F-­‐EMSAmeasurements (Ki, app, F-­‐EMSA = 18 ± 9). Third, I assessed esterification or othermodification of the carboxylate group. Oleamide, ethyl oleate, and 4-­‐methylumbelliferyl oleate failed to inhibit RNA-­‐binding. In contrast, the presence ofa Coenzyme A (CoA) substituent was apparently tolerated, although somedeacylation of acyl-­‐CoA stocks was apparent by thin layer chromatography. Fourth, Iassessed the requirement for the ω-­‐9 double bond. Stearic (18:0), palmitic (16:0),and myristic (14:0) acids failed to inhibit Msi1 RNA-­‐binding activity, indicating thatthe ω-­‐9 double bond is required. Surprisingly, the orientation of the double bond isalso critical. Elaidic acid (18:1, ω-­‐9 trans) has the same molecular weight as oleicacid, and nearly identical refractive index and molar aqueous solubility (~10 mM atpH 8.0), but its ω-­‐9 double bond is trans rather than cis. Elaidic acid did not inhibit
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Msi1 (Figure 2.2B). Linoleic (18:2, ω-­‐9, ω-­‐6) and arachidonic (20:4, ω-­‐12, ω-­‐9, ω-­‐6,
ω-­‐3) polyunsaturated fatty acids also inhibit Msi1, but with a weaker apparentinhibition constant (Linoleic acid: Ki, app, FP = 2.2 ± 0.2 µM, Ki, app, F-­‐EMSA = 1.2 ± 0.03
µM; Arachidonic acid: Ki, app, FP = 3.0 ± 0.2 µM, Ki, app, F-­‐EMSA = 1.1 ± 0.3 µM). Together,this data indicates that omega-­‐9 cis unsaturated fatty acids between 18 and 22carbons specifically inhibit Msi1 RNA-­‐binding activity and identify erucic acid as themost potent inhibitor (Table 2.1). MSI2 was inhibited with similar specificity (Figure2.4).
Oleic acid directly interacts with the RRM1 of Msi1 to affect inhibitionIn principle, inhibitory fatty acids could inhibit by interacting with eitherMsi1 or its RNA target. If the fatty acid bound to the RNA-­‐binding domain of Msi1,the interaction might alter the local environment of its single tryptophan (W29),leading to a measurable change in the intrinsic fluorescence (Vivian and Callis2001). To test this hypothesis, I titrated oleic acid or elaidic acid (trans-­‐oleic acid)into recombinant Msi1 protein or n-­‐acetyl-­‐L-­‐tryptophanamide (NATA) andmeasured tryptophan fluorescence. NATA is a compound that contains a singletryptophan as a control for non-­‐specific association and fluorescence quenching.Titration of oleic acid, but not elaidic acid, strongly quenched tryptophanfluorescence and altered the emission intensity curve shape from 300 to 400 nm(Figure 2.5 and figure 2.6). However, neither compound affected the fluorescence ofNATA. In my buffer system, the maximal emission for both NATA and Msi1 is 350
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Figure 2.4: RNA binding specificity and inhibition by specific fatty acids is conservedin MSI2. (A) MSI2 binds the RNA aptamer CCCR005 with similar affinity to that ofMsi1 by both FP and F-­‐EMSA. The no protein control lane defines the position of freeRNA. Data are the average and standard deviation of three independentexperiments. (B) MSI2 is specifically inhibited by oleic acid and eicosenoic acid in FPand F-­‐EMSA dose response experiments. No compound and no protein controlsdefine the position of bound and free RNA respectively. Data are the average andstandard deviation of three independent experiments.
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Figure 2.5: Msi1 tryptophan fluorescence at 350 nm as a function of oleic and elaidicacid. The Kd, app , Ki, app, and Hill parameters are the average and standarddeviation of three independent replicates.
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Figure 2.6: The Msi1 tryptophan fluorescence spectrum changes as a function ofinhibitor titration. The tryptophan fluorescence emission spectrum is stronglyquenched upon oleic acid (A) and erucic acid (C) but not elaidic acid (B) addition.(D) A tryptophan-­‐containing control N-­‐acetyl-­‐tryptophanamide (NATA) does notchange upon compound addition. Data from one representative experiment for eachcompound concentration are shown.
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nm (Figure 2.6). I fit the emission at 350 nm to a quadratic, bimolecular associationmodel in order to determine the apparent dissociation constant. The Kd, app of oleicacid was 2.6 ± 1 µM, essentially identical to the Ki, app determined by FP and F-­‐EMSAdose response experiments (Table 2.1, Figure 2.5A). These data are consistent withinhibition resulting from a direct association of oleic acid with the Msi1 protein.The NMR structures of Msi1 RRM1 and RRM2 in the absence and presence ofRNA show that both domains adopt the canonical RRM fold in which an anti-­‐parallelbeta sheet is buttressed by two alpha helices (Figure 2.7) (Nagata et al. 1999;Miyanoiri et al. 2003; Ohyama et al. 2011). In RRM domain proteins, the beta sheetsurface typically forms the RNA-­‐binding platform (Figure 2.7) (Kielkopf et al. 2004;Clery et al. 2008). In the RNA-­‐bound structure, several conserved amino acidslocated on the beta sheet surface and loops make sequence-­‐specific contacts to theRNA (Ohyama et al. 2011). Notably, W29 directly contacts RNA by stacking on thefirst purine nucleotide. Tryptophan fluorescence experiments reveal that oleic acidbinding causes W29 fluorescence quenching (Figure 2.5), suggesting that bindingchanges the environment surrounding this amino acid. As such, fatty acid bindingmay inhibit Msi1 RNA-­‐binding by an allosteric mechanism.To assess whether oleic acid association induces a change in Msi1 secondarystructure, a collaborator collected circular dichroism spectra as a function of fattyacid treatment. We observe a decrease in mean residue ellipticity centered around220 nm upon treatment with oleic acid but not elaidic acid (Figure 2.8). Todetermine whether the spectral changes correspond to a change in oligomerization
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Figure 2.7: Musashi-­‐1 RRM1 and RRM2 NMR structures. Ribbon model of Msi1RRM1 (top). Space-­‐filling model of Msi1 RRM1 (middle) and RRM2 (bottom)(Nagata et al. 1999; Miyanoiri et al. 2003). Left, β-­‐sheet surface, right, α-­‐helicalsurface. Conserved phenylalanines and W29 are green. Lysine and arginine residuesare blue. A hydrophobic pocket exists on the RRM1 α-­‐helical surface.
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Figure 2.8: CD and AUC characterization of oleic acid association. (A) CD spectra ofMsi1 RRM1 in the presence of oleic (top) or elaidic acid (bottom). (B) Differencespectra calculated for the far-­‐UV CD spectra of Msi-­‐1 collected at increasing oleicacid concentrations relative to the spectrum in the absence of oleic acid. Differentcolors correspond to different concentration of oleic acid: red is 3 μM, purple is 6μM, blue is 12.5 μM, green is 25 μM and black is 50 μM. The inset shows the samedifference spectra calculated for the CD spectra of Msi1 with increasing elaidic acidconcentration relative to the spectrum collected in the absence of elaidic acid. Thesame color scheme applies to the different elaidic acid concentrations. (C) Envelopetraces of the van Holde-­‐Weischet analysis for analytical ultracentrifugationexperiments of Msi1 alone (top), with oleic acid (middle) and with elaidic acid(bottom). The predominant species sediments where monomeric Msi1 would beexpected, and there is no significant change in the sedimentation profile afteraddition of oleic or elaidic acid. Data are representative traces from one of threeindependent experiments.
77
state, I performed velocity sedimentation analytical ultracentrifugation experiments(Demeler et al. 2011). There was no significant change in the velocity sedimentationprofile of Msi1 by van Holde-­‐Weischet analysis after adding either oleic acid orelaidic acid, and the predominant species remains monomeric (Figure 2.8C)(Demeler and van Holde 2004; Demeler et al. 2011). These data indicate that oleicacid binding alters the secondary structure of Msi1, but this transition does notappear to induce aggregation at concentrations below the CMC.The published NMR structures of Msi1 in its apo form show a hydrophobiccavity on the alpha-­‐helical surface of RRM1, opposite the RNA-­‐binding surface(Figure 2.7) and adjacent to W29 (Nagata et al. 1999; Miyanoiri et al. 2003). Msi1RRM2 does not have this feature. I hypothesized that this cavity comprises the fattyacid binding site. To test this idea, I first asked whether RRM1 is sufficient for ω-­‐9fatty acid inhibition. I purified his6-­‐tagged Msi1 RRM1 (amino acids 7-­‐103) andused FP and F-­‐EMSA to determine whether RRM1 is sufficient for both RNA bindingand inhibition by oleic acid. RRM1 bound to the aptamer RNA with an apparent Kd of75.2 ± 10 nM by FP (Figure 2.9A). Addition of oleic acid but not elaidic acid inhibitsRNA-­‐binding activity with similar Ki, app compared to the full RNA-­‐binding domain(Figure 2.9B). Thus, RRM1 is sufficient for RNA recognition and fatty acid inhibition.Next, I prepared a 15N labeled sample of RRM1 for NMR spectroscopy. Ourcollaborators collected an 15N-­‐1H HSQC spectrum, and titrated aptamer RNA toidentify amide proton chemical shift differences associated with RNA binding(Figure 2.9C). The majority of the chemical shift differences map to the β-­‐sheet
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Figure 2.9: NMR characterization of Msi1 RRM1. (A-­‐B) Recombinant His6-­‐taggedMsi1 RRM1 binds RNA aptamer CCCR005 (A) and is inhibited by oleic acid (B). FPdata is reported as the average and standard deviation of three independentexperiments. (C) 2D 1H-­‐15N HSQC spectra of Msi1 free (red) and bound to RNA(blue) at pH 7 and 25 °C. Selected resonances are labeled and enlarged in the insets.Crosspeaks are colored according to the increasing concentration of added RNA. (D-­‐F) NMR titration of oleic acid (D) The cross peak intensities (I) from the 2D 1H-­‐15NHSQC spectra of Msi1 are plotted for four representative residues (Q30 black, R82green, K98 red, A100 blue) as a function of the concentration of oleic acid added tosample of 133 μMMsi1 at pH 7 and 25 °C. The intensities are normalized relative tothe measured intensity in the absence of oleic acid, I0. The intensity ratios werefitted to straight lines. (E) The cross peak intensities for all assigned residues ofMsi1 in the 2D NMR spectrum after adding 0.22 molar equivalents of oleic acid. I0 isthe intensity without oleic acid addition and I0.22 is the intensity after addition of0.22 molar equivalents of oleic acid. Each point represents the I0.22/I0 for a singleresidue. The average of all intensities at I0.22 (solid line) and ± 1 standard deviation(dashed lines) indicate that some residues lose more intensity than others. Anumber of residues display normalized intensity values that are higher (blue) orlower (red) than 1 standard deviation from average. (F) Space-­‐filling model of Msi1RRM1 (Nagata et al. 1999; Miyanoiri et al. 2003). Residues with intensities below 1sd from the average are red. Residues with intensities higher than 1 sd from theaverage are blue.
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surface and the loops, which is typical for RRM proteins. Notably, backbone amideprotons corresponding to F23, G64, and F65, display large chemical shift changesupon RNA binding. In contrast, chemical shift changes on the α helical face aresmall. The data are consistent with the model in which the β-­‐sheet recognizes RNAand binding involves a structural transition including F23, G64, and F65 (Ohyama etal. 2011). Next, oleic acid or elaidic acid was titrated into the sample of Msi1 RRM1(Figure 2.9D-­‐F). We expected to observe chemical shift changes associated witholeic acid binding to the protein. The addition of increasing amounts of oleic acid didnot result in significant changes in chemical shifts but in considerable reduction ofthe peak intensities and in line broadening. The largest loss of signal upon additionof substoichiometric concentrations of oleic acid was observed for W29, Q30, L36,C49, L50, R53, S60, G62, V74, T89, and K98 (Figure 2.9E-­‐F). The observed loss ofsignal is likely due to chemical exchange between the free and bound state. Asexpected, we detected a strong loss in signal intensity across the entire proteinwhen the concentration of oleic acid exceeded the CMC (75 ± 8 µM, Figure 2.3B andFigure 2.9D-­‐F). The observed general loss of Msi1 signal is probably due toprecipitation of the protein-­‐oleic acid complex, or it could be attributed to theinteraction of Msi-­‐1 with oleic acid micelles, or both. We note that a precipitantforms in the NMR tube at elevated oleic acid concentration. Because the CMC ofoleic acid is below the concentration needed to make a saturated Msi1 sample(Figure 2.3B), we cannot form sufficient Msi1-­‐oleic acid complex for NMR structuralstudies.
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A model of the omega-­‐9 fatty acid inhibition mechanismBecause the high concentrations needed for NMR spectroscopic studiesprecluded direct measurement of the Msi1 fatty acid interface, we performedcomputational docking calculations with eicosenoic acid or oleic acid with Msi1RRM1 (Table 2.1, Figure 2.10A-­‐B) (Friesner et al. 2004; Friesner et al. 2006). In thedocked models, both compounds insert the ω-­‐9 end into the cavity, form extensivecontacts with the protein surface, and position their carboxy termini adjacent to apositively charged arginine side chain (R53 or R61, dependent on the model, Figure2.10, Figure 2.9D-­‐F). The docked model offers an explanation for the experimentallyobserved specificity of inhibition. Amide and ester derivatives lose the negativecharge and cannot form charge-­‐charge interactions with arginine (oleamide, ethyloleate). Shorter omega-­‐7 fatty acids will not fill the hole (palmitoleic acid).Modifications of the omega end limit insertion into the hole (ricinoleic acid).Eighteen carbons enable the carboxylate to reach R53 (oleic acid), (Figure 2.10).Twenty-­‐four carbons position the group beyond the arginine (nervonic acid). Transorientation of the double bond limits surface contact and prevents orientation of thecarboxylate towards R53 (elaidic acid). Finally, saturation of the double bond wouldrequire a large entropic penalty in order to adopt the necessary conformation(stearic acid).To further assess how fatty acid binding alters the dynamics of amino acidsthat contribute to RNA recognition, we performed molecular dynamics (MD)
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Figure 2.10: Docked model of Msi1 and oleic acid. (A-­‐B) Model of RRM1 bound tooleic acid (yellow) calculated by Schrödinger GLIDE (Friesner et al. 2004; Friesneret al. 2006). (C) Msi1 RRM1 overlays from two NMRmodels demonstrate the highlydynamic nature of loop 3. Arginine 53 (model 1) and arginine 61 (model 3) arepredicted to interact with the caboxylate of oleic acid in the respective models.
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simulations of the Msi1 RRM1 motif with and without oleic acid. The NMR structureof MS1 RRM1 served as the starting configuration for the free state (Nagata et al.1999; Miyanoiri et al. 2003). Three different models derived by docking oleic acidprovided the starting configurations for the oleic acid-­‐bound state (Friesner et al.2004; Friesner et al. 2006). Each of the four simulations was equilibrated for 1 nsand data were collected during a subsequent 30 ns trajectory. Upon oleic acidbinding, Msi1 underwent a transition to a more open state characterized by anincrease in solvent accessible surface area (SASA) and radius of gyration (Figure2.11A). Direct visualization of the structure’s time evolution showed that binding ofoleic acid is associated with stabilization of the C-­‐terminus of α-­‐helix 1, fraying of α-­‐helix 2 at both the N-­‐ and C-­‐termini and, in one trajectory, formation of an additional
β-­‐sheet in loop 5 (Figure 2.12). The computed probability of each residue to be in asecondary structural element (Figure 2.11C) supports our observations. Notably,the β-­‐sheet that forms in loop 5 is absent in the Msi1 apo structure but is present inthe structure of Msi1 bound to RNA, indicating that association with either RNA orinhibitor may induce secondary structural changes in loop 5 (Figure 2.12) (Ohyamaet al. 2011).Analysis of the structure and dynamics of Msi1 bound to oleic acid and itscomparison to the RNA-­‐bound structure suggests a mechanism of inhibition. Oleicacid binding stabilizes β-­‐strand formation in loop 5 and alters its position relative tohelix 1. The distance between the C-­‐terminus of α-­‐helix 1 and loop 5 in the free andoleic acid-­‐bound state is greater than that observed in the RNA-­‐bound state
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Figure 2.11: Molecular dynamics studies of Msi1 with oleic acid. (A-­‐B) represent thenormalized histograms of the protein solvent accessible surface area (SASA) andradius of gyration (rgyr) illustrating the structural transition undergone by the Msi1upon oleic acid binding. (A) SASA distributions calculated from the MD trajectoriesof Msi1 bound to oleic acid and of Msi1 in the apo state are represented in red andblack, respectively. (B) Radius of gyration distributions calculated from the MDtrajectories of Msi1 bound to oleic acid and of Msi1 in the apo state are representedin red and black, respectively. (C) The probability of being in an α-­‐helix or β-­‐sheet isshown for each residue of Msi1. The probabilities calculated for each residue fromthe MD trajectories of Msi1 free and bound to oleic acid are shown in black and red,respectively. Oleic acid binding is associated with stabilization of the C-­‐terminus ofα-­‐helix 1, fraying of α-­‐helix 2, at both the N-­‐ and C-­‐termini, extension of sheet 2, aswell as the formation of an additional β-­‐sheet at loop 5 (L5). (D-­‐E) Normalizedhistograms of the distance between G35, located on α-­‐helix 1, and L85, located onloop 5, calculated from the MD trajectories of oleic acid-­‐bound Msi1 and of apo Msi1are shown in red and black, respectively. The distribution of distances between theCα atoms of G35 and L85 is depicted in (D). The distribution of distances betweenthe Cα of G35 and the Cδ2 of L85 is shown in (E). The green lines show the values ofthese distances observed in the NMR structure of Msi1 bound to RNA (PDB ID2RS2). In the oleic-­‐bound state, loop 5 is restricted in approaching α-­‐helix 1 due tothe steric hindrance of the oleic acid. (F-­‐G) Normalized histograms of tworepresentative side chain distances of W29 and Q30. Histograms calculated over the
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MD trajectories of oleic acid-­‐bound Msi1 are shown in red, those of apo Msi1 inblack. The distance between W29 Cε2 and Q30 Cγ is shown in (F). The distancebetween W29 Cζ2 and Q30 Nε2 is shown in (G). The green lines show thesedistances observed in the NMR structure of Msi1 bound to RNA (PDB ID 2RS2). Inthe oleic-­‐bound state, the side chain of W29 is stacked against the side chain of Q30.This conformation of W29 is not observed in either the free or RNA-­‐bound states ofMsi1.

89
Figure 2.12: MD model of Msi1 with oleic acid. (A) Overlay of the oleic acid boundMD simulation (gray and red) with the apo-­‐state NMR structure (gray and blue)(Ohyama et al. 2011). (B) RNA contact residues (red) in loop 5, helix 2, and strand 4of the β-­‐sheet are perturbed in oleic acid-­‐bound molecular dynamics simulation(Ohyama et al. 2011).
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(Figure 2.12, Figure 2.11). The presence of oleic acid blocks loop 5 fromapproaching the C-­‐terminus of α-­‐helix 1. When loop 5 is in the more openconformation, K88 is not in position to interact with the first purine nucleotide ofthe consensus, in this case Gua1. In addition, binding of oleic acid causes W29 tostack against the side chain of Q30. (Figure 2.13A-­‐B). This observation is inagreement with the NMR signal intensity loss observed for certain residues duringoleic acid titration (Figure 2.9D-­‐F), as well as the strong quenching of Msi1tryptophan fluorescence measured upon addition of oleic acid (Figure 2.5, Figure2.6). W29 directly stacks with the first RNA nucleotide, stabilizing the interactionbetween Msi1 and RNA. Stacking is eliminated in the presence of oleic acid (Figure2.13A-­‐B). Finally, strand 4 is more flexible in the oleic acid-­‐bound state than in freeMsi1 (Figure 2.13A-­‐B). Strand 4 contains several residues that directly contact RNA.The simulations suggest that oleic acid weakens these interactions. In contrast toour initial hypothesis, we do not observe a dramatic change in the dynamics of F65in the presence of oleic acid over the time course of the simulations.The circular dichroism and analytical ultracentrifugation data (Figure 2.8)are consistent with a net gain in secondary structure upon oleic acid binding, aspredicted by the MD simulation (Figure 2.11 and Figure 2.13). In addition, thechange in tryptophan fluorescence observed upon oleic acid but not elaidic acidtreatment is consistent with the changes in tryptophan solvent exposure observedin the simulation.
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Figure 2.13: MD comparison of RNA-­‐bound and oleic acid-­‐bound Msi1. (A-­‐B) Arepresentative snapshot from the MD simulation of Msi1 bound to oleic acid (white)compared to the Msi1-­‐RNA NMR structure (blue) (Ohyama et al. 2011). Panel (A)shows the Gua 1 binding pocket. In the oleic-­‐bound state, the open conformation ofloop 5 (L5) orients K88 such that K88 cannot contact Gua 1. W29 is stacked againstQ30 and unavailable for stacking against Gua 1. Interaction with the side chain ofR61 stabilizes the conformation of W29 in the oleic-­‐bound state. Panel (B) highlightsthe different conformations of residues that interact with Gua 1, Ura 2, Ade 3 andGua 4; represented in grey, orange, red and purple, respectively. (C) Difference ofthe mean Lipari-­‐Szabo order parameters by residue between the apo and oleic acid-­‐bound states of Msi1. The Lipari-­‐Szabo order parameters for the backbone NH bondvectors, S2, were calculated to quantify the backbone flexibility of the free and oleicacid-­‐bound form of Msi1. The difference of the order parameters, ΔS2 = S2apo -­‐S2MSI-­‐OA, indicates that Msi1-­‐oleic acid complex is more flexible than apo Msi1,with the few exceptions mostly observed at the N-­‐terminus. The secondarystructural elements are highlighted at the top. Error bars are calculated from thestandard deviation among trajectories.
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To test features of the model, I mutated residues predicted to interact witholeic acid (Figure 2.14) and measured the relative inhibition constant (Krel, app) bydose response FP. I observed no change in fatty acid inhibition when Q30 wasmutated to a glutamate (Krel, app = 0.9, Figure 3-­‐Figure 3 Supplement 1). Mutation ofH83 to leucine also had no effect on fatty acid inhibition. Mutation of H83 tophenylalanine reduced inhibition by almost 2-­‐fold. H83 lines the hydrophobicpocket. Mutation of this residue to phenylalanine is predicted to make the pocketnarrower. Mutation of G64 to alanine reduced inhibition by 3.1 fold. G64 forms thefloor of the hydrophobic pocket, mutation to an alanine is expected to make thepocket more shallow. Mutation of G35 to aspartate and glutamate results in a 2-­‐foldand 7-­‐fold reduction of inhibition, respectively. This is possibly due to the to theaddition of a negative charge near the mouth of the hydrophobic cavity.To test whether the R53 and/or R61, which are predicted to interact with thecarboxylate end of oleic acid, are important for inhibition, I made single glutamatemutations at each position (R53E or R61E). Oleic acid inhibition of the R53E mutantis reduced 3-­‐fold, while R61E is reduced 5-­‐fold. Mutating both arginines(R53E/R61E) increases this effect to 35-­‐fold. This indicates that R53 and R61 areboth important for inhibition, and act in a partially redundant way. A triple mutant(R53E/R59E/R61E) weakens inhibition by a similar amount (27-­‐fold). The R53Emutant has a small effect on RNA-­‐binding, while the R61E mutant has a strong
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Figure 2.14: Mutational analysis of Msi1 RRM1. (A) Space-­‐filling model of Msi1RRM1 with mutated residues colored. Orange residues indicate mutations withmodest (<2 fold) or no reduction in inhibition by oleic acid. Red residues displayed alarger (>2 fold) reduction in inhibition by oleic acid. (B) Table of mutant RNA-­‐binding and inhibition data. Data are the average of three independent fluorescencepolarization experiments. All proteins were purified and tested during the sametime period and using the same reagents, enabling comparison of wild type andmutant variants.
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18-­‐fold effect. The interaction of R61 with oleic acid would preclude its interactionwith RNA, and thus may contribute to the mechanism of inhibition.Together, the MD simulations and experimental data are consistent with anallosteric model of inhibition, wherein fatty acid binding induces a change inconformation that modifies the secondary structure of RRM1 and perturbs theposition of amino acids required for RNA recognition. Additional work will benecessary to determine whether fatty acid inhibition works via the mechanismsuggested by the computational docking and MD simulations or through analternative mechanism.
DiscussionThe data presented in this chapter illustrate the development of a smallmolecule screen for inhibitors of the RNA-­‐binding protein Msi1. In the pilot screen,four compounds inhibited RNA-­‐binding activity in both the high-­‐throughputscreening phase and the secondary screening phase. Of these, oleic acid was ofparticular interest due to its biological activity as an intermediary metabolite.MSI1 is implicated in neural and epithelial development, where it acts toprotect the proliferative capacity of stem and progenitor cells (Imai et al. 2001). Ourlab and the Armstrong lab have both observed a role for Msi1 in preventingdifferentiation of oligodendrocyte progenitor cells into mature oligodendrocytes(Dobson et al. 2008). MSI1 expression is lost as cells mature into their terminal
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identity, so it is perhaps not surprising that MSI1 might play a role in preventing thedifferentiation process.Myelin is an essential lipid-­‐rich membrane produced by matureoligodendrocytes. It serves to insulate and protect neuronal axons, thereforeenabling impulse propagation. Oleic acid is one of the most prevalent fatty acidsused in the production of the myelin membrane. It is interesting to note that thisfatty acid becomes more abundant in oligodendrocyte lineage cells as theydifferentiate and MSI1 expression and function is lost.A number of diseases are caused by myelin lesions or demyelination,including multiple sclerosis and Guillain Barre syndrome. Therapies for thesediseases are extremely limited, and a method for targeted re-­‐myelination has yet tobe found. If MSI1 inactivation in oligodendrocyte progenitor cells can inducedifferentiation into mature, myelin-­‐producing oligodendrocytes, it would present anattractive therapeutic target for these diseases. More work must be done tocharacterize the role of MSI1 in these cells, including a detailed study on themorphology and viability of the differentiated oligodendrocytes.Cancerous tumors often contain a population of highly-­‐proliferative ‘cancerstem cells.’ These cells display traits of stem and progenitor cells, but lack theproliferative regulation found in normal stem and progenitor cells. MSI1 is highlyexpressed in cancerous cells of neural and epithelial lineage, and high MSI1expression is correlated with metastasis and poor patient prognosis (Strojnik et al.
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2007; Fan et al. 2010; Wang et al. 2010; Vo et al. 2012b; Dahlrot et al. 2013; Kuanget al. 2013).Several labs have observed that MSI1 depletion in tumor cells leads todifferentiation and decreased proliferation (Sanchez-­‐Diaz et al. 2008; Sureban et al.2008; Wang et al. 2010). MSI1 has therefore gained notice as an attractivetherapeutic prospect in the ongoing search for cancer therapies. The small moleculescreen described here may prove useful in identifying inhibitors of MSI1 for use inboth cancer and myelin disease therapies.Oleic acid, while interesting for its role as a biological metabolite, is likely nota useful therapeutic molecule. It is a building block for membrane phospholipids,energy storage molecules, and lipid signaling molecules, and is therefore not amolecule that can be specifically used to target MSI1. Further screening efforts willbe necessary to yield a potent, non-­‐biological inhibitor of MSI1 for use in myelin andcancer therapeutic research.
Methods
PlasmidsDNA encoding the mouse Msi1 RNA binding domain fragment (amino acids 7-­‐192)was amplified from the mammalian gene collection (MGC) full-­‐length ORF clone100014969 (Invitrogen) using gene specific primers (forward primer: 5′-­‐cgcgcggatcccagcccggcctcgcctcccc-­‐3′; reverse primer: 5′-­‐gcgcgaagcttcggggacatcacctcctttg-­‐3′). This fragment was digested using BamHI and
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HindIII restriction enzymes and subcloned into a modified version of pET-­‐22bvector (Invitrogen) in which the pelB leader sequence was replaced with a His6-­‐Glytag followed by a TEV protease site to make pET-­‐22HT-­‐MSI1 (7-­‐192). Mutantversions of the MSI1 RNA binding domain were prepared by site-­‐directedmutagenesis using QuikChange (Stratagene). The human MSI2 RNA binding domainfragment (amino acids 8-­‐193) was amplified from MGC full-­‐length ORF clone3505639 using gene specific primers (forward primer: 5′-­‐cgcgcggatccggcacctcgggcagcgccaa-­‐3′; reverse primer: 5′-­‐gcgcgaagctttcatgggaacatgacttctttcg-­‐3′). This fragment was cloned into the BamHIand HindIII restriction sites of pET-­‐22HT to make pET-­‐22HT-­‐MSI2 (8-­‐193). TheMSI1 RRM1 plasmid pET-­‐22HT-­‐MSI1 (7-­‐103) was prepared by site-­‐directedmutagenesis using QuikChange (Stratagene) to replace M104 with an ochre stopcodon. Full-­‐length mouse Msi1 was amplified from MGC full-­‐length ORF clone100014969 (Invitrogen) using forward primer 5′-­‐cgcgcggatccatggagactgacgcgcccca-­‐3′ and reverse primer 5′-­‐ccgggcggccgctcagtggtacccattggtgaa-­‐3′. The resultingfragment was subcloned into pCDH-­‐CMV-­‐MCS-­‐EF1-­‐Puro (System Biosciences) usingthe BamHI and NotI restriction enzymes to make pCDH-­‐CMV-­‐MSI1(FL).
Purification of recombinant proteinsH6-­‐TEV-­‐MSI-­‐1 (7-­‐192), H6-­‐TEV-­‐MSI-­‐1 (7-­‐104), and H6-­‐TEV-­‐MSI-­‐2 (8-­‐294) wereexpressed and purified from Escherichia Coli BL21(DE3) cells. Liquid cultures grownat 37ºC were induced for 3 hours during mid-­‐log phase with 1 mM Isopropyl β-­‐D-­‐1-­‐
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thiogalactopyranoside (IPTG). Cells were pelleted, resuspended in lysis buffer (50mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole, 5 mM β-­‐Mercaptoethanol (BME)),and lysed using a microfluidizer (IDEX Health and Science). Soluble lysate wasapplied to a Ni-­‐NTA column (Qiagen), washed with wash buffer (50 mM NaH2PO4,300 mM NaCl, 50 mM Imidazole, 5 mM BME), and eluted with elution buffer (50 mMNaH2PO4, 300 mM NaCl, 300 mM Imidazole, 5 mM BME). Fractions were analyzed bySDS-­‐page and those containing recombinant MSI1 or MSI2 were pooled and dialyzedovernight into S buffer (50 mMMOPS pH 6.0, 20 mM NaCl, 2 mM DTT). Pooledfractions were applied to a HiTrap SP cation exchange column (GE Healthcare) andeluted using a gradient of 0.1M to 1 M NaCl in S Buffer. Fractions containing MSI1 orMSI2 were pooled and dialyzed overnight into Q buffer (50 mM Tris pH 8.8, 20 mMNaCl, 2 mM DTT) prior to loading a HiTrap Q anion exchange column (GEHealthcare). The protein was eluted over a gradient from 0.1 to 1 M NaCl in Q buffer.Fractions containing MSI were pooled and dialyzed using Spectra/Por 7 25 kD(MSI1) or 10 kD (MSI2) molecular weight cutoff tubing (Spectrum laboratories)overnight into storage buffer (50 mM Tris pH 8.0, 20 mM NaCl, 2 mM DTT). Theyield of >95% pure MSI1 or MSI2 is typically 20 mg per liter of culture (Figure 2.1).
RNA sequences and labelingSynthetic RNA oligonucleotides were ordered from IDT and 3′ end-­‐labeled withfluorescein 5-­‐thiosemicarbazide (Invitrogen) according to the method of Reines andCantor (Reines and Cantor 1974; Pagano et al. 2007; Farley et al. 2008). Briefly,
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5x10-­‐10 mol of RNA were incubated with 100 mM NaOAc, pH 5.1 and 5 nmol ofNaIO4 for 90 minutes at room temperature then ethanol precipitated. The RNA wasresuspended in 50 µl of 1 mM fluorescein-­‐5-­‐thiosemicarbazide in 100 mM NaOAc,pH 5.1. After incubating overnight at 4 °C, the RNA was separated from unreactedlabel by ethanol precipitation and subsequently passaged through a Piercecentrifuge column packed with Spehadex G-­‐25 resin (GE Healthcare). RNA CCCR005was a truncated form of the SELEX aptamer S8-­‐13 identified by the Okano lab (Imaiet al. 2001). In preparation for the small molecule screen, fCCCR005(AGCGUUAGUUAUUUAGUUCG/36-­‐FAM/) was ordered pre-­‐labeled from IDT.
Fluorescence polarization and electrophoretic mobility shift assaysFluorescence polarization (FP), also known as fluorescence anisotropy, andFluorescence electrophoretic mobility shift assays (F-­‐EMSA) were used to measurethe binding affinity of recombinant MSI1 to fluorescein-­‐labeled RNA aptamers.Assays were conducted as described in Pagano, et al. (Pagano et al. 2011). Briefly, 2nM fluorescein-­‐labeled RNA was incubated with varying concentrations ofrecombinant purified MSI1 protein in equilibration buffer (37.5 mM Tris pH 8.0, 75mM NaCl, 0.0075% igepal, 0.0075 mg/mL tRNA) for three hours. Fluorescencepolarization was determined with a Victor V3 plate reader using a 480 ± 31 nmexcitation filter and a 535 ± 40 nm emission filter. After measuring FP, the sampleswere mixed with 6x bromocresol green loading dye (0.15% (w/v) Bromocresolgreen, 30% (v/v) glycerol) and run on a 5% native polyacrylamide gel at 120V for
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75 minutes at 4ºC. Wet gels were scanned with a Typhoon FLA 9000 Biomolecularimager (GE healthcare) using a 473 nm laser and a long-­‐pass cut-­‐off filter (510 nm).The fraction of bound RNA was determined by quantifying lower (free) and upper(bound) band intensities using MultiGauge and ImageGauge software (Fujifilm). ForRNA sequences with two shifted species, the bands were quantified together.Polarization values or the fraction of bound RNA were plotted as a functionof protein concentration and fit to the Hill equation (1) to determine the apparentdissociation constant (Kd) and the apparent Hill coefficient (n). The upper (m) andlower (b) values were also fit in order to define the assay window.
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For RNA sequences where a bi-­‐phasic transition was observed, the FP datawere fit using a two-­‐site model (equation 2) to determine both apparentdissociation constants (Kd1 and Kd2) and the fraction (F) of signal that correspondsto each transition.
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Small molecule screenThe small molecule screen was performed at the UMass Medical School SmallMolecule Screening core facility using a variation of the FP assay described above.100 nM recombinant MSI1 protein and 2 nM fluorescein-­‐labeled RNA aptamerCCCR005 were added to each assay well of 384-­‐well black plates (Corning) using a
µFill liquid dispenser (BioTek). Compounds dissolved in DMSO from the LOPAC andChembridge libraries of small molecules were spotted in each assay well to a finalconcentration of 384 µM using a Tecan genesis workstation 150. Sixty-­‐four wells ofeach plate were reserved for controls, including thirty-­‐two wells that included noprotein and no compound (free RNA), and 32 wells that included protein, RNA, andDMSO (no compound). Plates were equilibrated at 25ºC prior to collectingpolarization and fluorescence intensity data for each well using a Victor V2V platereader (Perkin Elmer). The Z′ score, a measure of signal-­‐to-­‐noise, was calculated foreach plate using the average (µ) and standard deviation ( ) of the control wells(equation 3).
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Plate reads with a Z′ of < 0.5 were repeated. The average Z′ of all plates was 0.7 ±0.2. The polarization values (mP) of each well were normalized against the assay
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window using the mean polarization values of the no protein control (µ2) and nocompound control (µ1) wells to generate an assay score (equation 4).
 
Score = mP − µ2
µ1 − µ2
(4)
Hits were classified as wells with a score of 0.1 or less where the fluorescenceintensity remained within 2-­‐fold of the control average to eliminate false positivesdue to compound fluorescence or quenching.
Dose response experimentsDose response experiments to assess inhibition activity were performed using amodified FP and F-­‐EMSA protocol. A constant concentration of sub-­‐saturatingprotein was equilibrated with 2 nM fluorescein-­‐labeled RNA and varyingconcentrations of compound in equilibration buffer. The FP and F-­‐EMSA data werecollected as above and fit to a sigmoidal dose response equation to determine theIC50 (equation 5).
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The apparent inhibition constant was calculated using the Lin and Riggs conversion(equation 6), which corrects for the equilibrium dissociation constant of MSI1 forthe labeled RNA as well as the concentration of labeled RNA and protein used in theexperiment (Lin and Riggs 1972; Ryder and Williamson 2004).
 
Ki,app =
2 Kd( ) IC50( )
2P − R − 2Kd
(6)
Intrinsic tryptophan fluorescence assayTo directly assay the association of fatty acids and MSI1 protein, 6 µM MSI1 or N-­‐acetyl-­‐tryptophanamide (NATA) was incubated with varying concentrations ofcompound. Equilibrated reactions were excited at 280 nm, then steady-­‐statefluorescence emission spectra were recorded between 295 and 400 nm in one nmintervals using a T-­‐format Fluorolog fluorimeter (Horiba). 350 nm emission datawere normalized and fit to a quadratic bimolecular association curve (equation 7) todetermine the apparent dissociation constant, where C is the total compoundconcentration, P is the total protein concentration, and m and b represent themaximal and minimal signal, respectively.
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In-­‐silico Docking analysisThe ligand molecules were downloaded from the PubChem database(pubchem.ncbi.nlm.nih.gov) and prepared for docking using the LigPrep module inMaestro (Schrödinger, LLC). The target protein structures were downloaded fromthe PDB (www.rcsb.org) and prepared for docking in Maestro (Schrödinger, LLC)using the Protein preparation wizard. Glide (Schrödinger, LLC) was used to generatethe receptor grid for subsequent docking and scoring the docked ligands inStandard Precision (SP) mode. The pose with best Glide score from eachligand/receptor docking run was selected for further analysis (Friesner et al. 2004;Halgren et al. 2004; Friesner et al. 2006).
NMRLabeling with 15N was performed by growing cells in isotopically enriched M9medium, 1g 15NH4Cl per liter. 2D 1H-­‐15N HSQC spectra were collected using samplesof U-­‐15N MSI1 in 90% H2O/10% D2O buffer solution of 50 mM Tris at pH 7.0. 2D 1H-­‐
15N HSQC spectra were collected for each incremental addition of the unlabeledligand (either aptamer RNA, oleic acid, or elaidic acid) to the 15N MSI1 sample todetermine amide proton chemical shift changes upon titration of the ligand. Allexperiments were performed at 600 MHz on a Varian Inova spectrometer equippedwith a triple-­‐resonance cold probe at 298° K. Data processing was performed usingNMRPipe (Delaglio et al. 1995) and sparky (Goddard and Kneller) software.
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Molecular dynamics simulationWe performed molecular dynamics (MD) simulations of the RRM1 domain of MSI1(residues 20-­‐96) free and bound to oleic acid. We modeled the unknown structureof MSI1 bound to oleic acid by starting from the NMR solution structure of MSI1RRM1 (Miyanoiri et al. 2003; Ohyama et al. 2011) and docking the oleic acid ligandusing the GLIDE software package from Schrödinger, LLC (Friesner et al. 2006),followed by energy minimization and equilibration. All structures were solvated andneutralized in a TIP3P water box (Jorgensen et al. 1986). Energy minimization andMD simulations were subsequently carried out using the NAMD software package(Phillips et al. 2005) and using the version 27 CHARMM potential energy function(MacKerell et al. 1998). The particle mesh Ewald method (Darden et al. 1993;Essmann et al. 1995) was used to treat electrostatic interactions and periodicboundary conditions were applied throughout. The SHAKE algorithm (Ryckaert etal. 1977) was applied throughout the simulation to constrain the hydrogen atombond lengths at their equilibrium values and an integration time step of 2 fs wasused. After an initial energy minimization, the system was simulated in theisothermal-­‐isobaric ensemble. Non-­‐bonded interactions were calculated every timestep using a cut-­‐off distance of 12 Å. After equilibration in the isothermal-­‐isobaricensemble, an additional stage of equilibration was performed in the microcanonicalensemble. We then collected three independent 30 ns constant-­‐NVE productionruns of MSI-­‐1 bound to oleic acid and one for MSI-­‐1 in the free state at an average
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temperature of 298° K.Visualization and secondary structure analysis was performed in VMD, using theSTRIDE method (Frishman and Argos 1995).In addition, we employed a number of measures to characterize thestructural and dynamical changes between the free and bound state of MSI-­‐1,including the radius of gyration, the solvent accessible surface area (SASA), distancebetween backbone and/or side chain atoms of residues G35-­‐L85 and W29-­‐Q30, andLipari and Szabo order parameters (Lipari and Szabo 1982; Humphrey et al. 1996).These quantities were calculated using VMD (Humphrey et al. 1996) software alongwith bespoke programs previously described elsewhere (Morgan and Massi 2010).
Circular dichroismFar-­‐UV circular dichroism (CD) spectra were collected using 10 µMMSI1 in 50 mMTris pH 8.0, 100 mM NaCl and 0.1% TFE on a Jasco-­‐810 spectropolarimeter (JascoInc., Easton, MD). Spectra were collected from 215-­‐260 nm in a 0.2 cm path lengthquartz cuvette using a scan rate of 20 nmmin-­‐1 and a response time of 8 s. Thesample temperature for all CD measurements was maintained at 293° K.
Analytical ultracentrifugationSedimentation velocity analyses were conducted using a Beckman Optima XL-­‐Ianalytical ultracentrifuge in the University of Massachusetts Medical SchoolUltracentrifuge Facility. Data were analyzed with UltraScan III version 1.0 (Demeler
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et al. 2011). Sedimentation velocity experiments were performed with 45 μMMSI1in storage buffer (50 mM Tris-­‐HCl pH 8.0, 20 mM NaCl, 2 mM DTT). Measurementswere made at 20°C using an AN60ti rotor at 20000 rpm and 280 nm in intensitymode. Partial specific volumes were estimated on the basis of peptide sequence withUltraScan and found to be 0.7280 cm3/g for the MSI1 RBD. Data were analyzed bytwo-­‐dimensional spectrum analysis with simultaneous removal of time and radiallyinvariant noise (Demeler et al. 2009; Brookes et al. 2010). Noise and diffusion-­‐corrected, model-­‐independent sedimentation coefficient distributions weregenerated using the enhanced van Holde-­‐Weischet analysis (Demeler et al. 1997;Demeler and van Holde 2004).
Critical micelle concentration determination
The critical micelle concentration (CMC) for oleic acid in equilibration buffer wasdetermined using N-­‐phenyl-­‐1-­‐naphthylamine (NPN), a compound that fluoresceswhen sequestered into micelles (Hagihara et al. 2002; Hasegawa et al. 2008). 25 µMNPN was incubated with varying amounts of oleic acid for 30 minutes. Fluorescenceintensity was determined with a Victor V3 plate reader using a 355 nm excitationfilter and a 460 nm emission filter. Fluorescence intensity data were plotted as afunction of fatty acid concentration. The CMC was determined by a two statesegmented linear regression to identify the breakpoint between baselinefluorescence and fluorescence caused by NPN association with micelles.
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Chapter III: Musashi-­‐1 and the lipid biosynthetic enzyme stearoyl-­‐
CoA desaturase participate in a feedback loop to regulate cellular
proliferation.
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AbstractGene expression and metabolism are coupled at numerous levels. Cells must senseand respond to nutrients in their environment, and specialized cells must synthesizemetabolic products required for their function. Pluripotent stem cells have theability to differentiate into a wide variety of specialized cells. Howmetabolic statecontributes to stem and progenitor cell proliferation and differentiation is notunderstood. Data from the previous chapter showed that RNA-­‐binding by Musashi-­‐1is allosterically inhibited by 18-­‐22 carbon ω-­‐9 monounsaturated fatty acids. Musashiproteins are critical for development of the brain, blood, and epithelium. In thischapter I present data indentifying the lipogenic enzyme stearoyl-­‐CoA desaturase-­‐1(SCD1) as a MSI1 target. SCD products are used in essential cellular processesincluding proliferation, revealing a feedback loop between ω-­‐9 fatty acidbiosynthesis and MSI1 activity.
IntroductionDuring development, stem and progenitor cells give rise to the cells thatcomprise mature tissues and organs in response to a myriad of temporal and spatialregulatory signals. After development, small populations of these immature cellsremain to repair damage and replace cells that die or are selectively culled.Cancerous tumors often result when the proliferation machinery in these immaturecells becomes deregulated. Although the factors controlling proliferation and
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differentiation in these cells are not yet understood, the dual RRM RNA-­‐bindingprotein MSI1 likely plays a role in these processes.MSI1 is highly expressed in neural and epithelial progenitor cells, where itpromotes proliferation and prevents differentiation (Kayahara et al. 2003;Nishimura et al. 2003; Potten et al. 2003; Akasaka et al. 2005; Asai et al. 2005; Colittiand Farinacci 2009; Murayama et al. 2009). MSI1 is also highly expressed many incancers of neural and epithelial origin (Strojnik et al. 2006; Fan et al. 2010; Wang etal. 2010). MSI1 depletion results in decreased proliferation, increased apoptosis,and reduced tumor xenograft growth (Sanchez-­‐Diaz et al. 2008; Sureban et al. 2008;Wang et al. 2010). Additionally, poor patient prognosis is correlated with high MSI1expression in tumors of neural and epithelial lineage (Strojnik et al. 2007; Wang etal. 2010; Vo et al. 2012b; Dahlrot et al. 2013).These data implicate MSI1 as a logical therapeutic target for various cancersand diseases of neural and epithelial lineage tissues. However, the mechanisms thatgovern MSI1 expression are not yet known. There is evidence that certain microRNAs, post-­‐transcriptional regulatory factors, transcription factors, and cyclin-­‐dependent and mitogen-­‐activated protein kinases may regulate MSI1 activity, but itis not clear whether regulation is direct or indirect (Vo et al. 2011; Arumugam et al.2012; Vo et al. 2012a; Pasto et al. 2014). The data presented in chapter II show thatMSI1 is allosterically inhibited by a class of intermediary metabolites, including oleicacid. This data provides a link between the post-­‐transcriptional regulation ofproliferation and metabolic state.
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In the current chapter, I present data that further strengthen the linkbetween MSI1-­‐mediated post-­‐transcriptional regulation and metabolism. Here, thelipid biogenic enzyme stearoyl-­‐CoA desaturase (SCD) is implicated as a novel MSI1regulatory target. SCD is the rate-­‐limiting enzyme in the production of omega-­‐9unsaturated fatty acids and is therefore essential for proliferation, energy storage,and lipid signaling. I propose a feedback loop involving SCD and MSI1 to regulateproliferative homeostasis in healthy neural and epithelial lineage cells.
Results
Oleic acid treatment reduces oligodendrocyte progenitor cell proliferationTo understand how fatty acids regulate MSI1, I investigated the effect oftreating the immortalized rat oligodendrocyte progenitor cell line CG-­‐4 with oleicacid (Louis et al. 1992). CG-­‐4 cells maintain normal precursor cell morphology, canbe readily transfected, and can be induced to differentiate into matureoligodendrocytes by withdrawal of growth factors (Franklin et al. 1995) (Louis et al.1992). I observed that CG-­‐4 cells undergo a lipid profile shift upon differentiation,as detected by quantitative lipidomics mass spectrometry (Figure 3.1). As withprimary OPCs, Msi1 is expressed strongly in the precursor state but decreases upondifferentiation (OPCs: 1.0 ± 0.3, oligodendrocytes: 0.15 ± 0.01, p-­‐value = 0.0035).Treatment of CG-­‐4 OPCs with oleic acid strongly inhibited the rate of cellproliferation (Figure 3.2), matching the published phenotype of Msi1 knock down inprimary OPCs (Dobson et al., 2008).. In contrast, treating HEK293T cells—which do
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Figure 3.1: Lipidomics analysis of undifferentiated and differentiated CG4oligodendrocyte progenitor cells (A) Scatter plot of lipidomics data fordifferentiated vs undifferentiated CG4 cells. Data are reported as nMoles per millioncells. Red data points indicate lipids that are significantly different afterdifferentiation (FDR = 5%). (B) Volcano plot of lipidomics data. Dashed lines denotefold-­‐changes of ±1.5 and ±3. Red data points indicate lipids that are significantlydifferent after differentiation (FDR = 5%).
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not express Msi1—with the same concentration of oleic acid had little or no effecton the rate of proliferation. Treatment with stearic acid, which does not inhibitMSI1, had no effect on proliferation rate in either cell type (Figure 3.2). The datasuggest that reduction of Msi1 activity by oleic acid limits proliferation, but there isa possibility that the fatty acid modulates other cellular pathways that contribute toproliferation.
MSI1 regulates stearoyl-­‐CoA desaturaseBecause metabolic homeostasis is often regulated though feedback loops, it ispossible that MSI1 might control the expression of enzymes required to make longchain monounsaturated fatty acids. In humans, non-­‐dietary oleic acid is producedfrom stearic acid by SCD. Expression of SCD is tightly controlled at thetranscriptional, post-­‐transcriptional, and post-­‐translational levels. In rodents, thereare four SCD genes, Scd1-­‐4. I used FP and F-­‐EMSA assays to test the ability ofrecombinant Msi1 to bind each of seven putative consensus sites present in the Scd13′ UTR (Figure 3.3). Msi1 binds to all seven sites by FP and F-­‐EMSA (Figure 3.3B).Site 2 and site 7 bind to Msi1 with comparable affinity to the selected aptamer. Theslightly decreased binding affinity measured for these 7 fragments is likely due tothe fact that aptamer CCCR005 contains two Msi1 binding sites, while each Scd1 3′UTR fragment contains only a single Msi1 binding site. Transcripts encoding SCD1co-­‐immunopreciptated with Msi1 from CG-­‐4 cell extracts using two independentantibodies (Figure 3.4A). Similar results were obtained with NumbmRNA, a positive
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Figure 3.2: Fatty acid treatment of CG-­‐4 OPCs (A) Dose response for oleic acidtreatment in cell culture. HEK293T (dashed) and CG-­‐4 (solid) cell proliferation as afunction of increasing oleic acid (red = 50 µM, grey = 5 µM black = 0 µM). The data isthe average and standard deviation of at least three biological replicates. (B)HEK293T (dashed) and CG-­‐4 (solid) cell proliferation as a function of oleic acid orstearic acid treatment (red = treated, black = untreated). The data is the average andstandard deviation of at least three biological replicates.
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Figure 3.3: SCD1 is a putative Msi1 target. (A) There are seven MSI1 consensus sitesin the 3’-­‐UTR of Scd-­‐1 mRNA. The Kd, app is the average and standard deviation ofat least three experiments. (B) MSI1 binds each of 7 SCD1 3’ UTR fragmentscontaining the MSI1 consensus sequence (G/A)U1-­‐3AGU with variable affinity. FPand F-­‐EMSA binding experiments are reported as the average and standarddeviation of three independent experiments.
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Figure 3.4: Msi1 is a positive regulator of SCD. (A) Scd-­‐1 transcripts co-­‐immunoprecipitate with anti-­‐Msi1 antibodies. The data were quantified using a FUJIFLA-­‐5000 imager. (B) Western analysis of SCD expression in HEK293T cells. Thedata were quantified using the LICOR Odyssey system relative to non specific bands(** and *, Figure 6-­‐figure 6 supplement 2B) to control for loading. The average andstandard deviation of at least three independent experiments is shown. (C) TheSCD1 antibody is specific for full-­‐length SCD1 and the associated proteolysisproducts. Two independent shRNA constructs reduced full-­‐length SCD1 andassociated proteolysis products compared to non-­‐transfected or control shRNAtransfected HEK293T cells. (D) qRT-­‐PCR of SCD1 mRNA. The data are the mean andSD of the fold-­‐change in SCD1 mRNA from 5 independent experiments. Eachexperiment comprised 3 technical replicates normalized to tubulin or GTF2i.
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control. Overexpression of Msi1 in HEK293T cells, which do not endogenouslyexpress MSI1, increased the amount of SCD and SCD proteolysis products by 2.5 ±0.35 fold (p-­‐value = 0.018, Figure 3.4B-­‐C). I was unable to detect SCD expression inthe rat CG-­‐4 cells using available antibodies. qRT-­‐PCR analysis of HEK293T mRNAshows a slight but non-­‐significant increase in SCD1 transcript abundance upon Msi1overexpression (Figure 3.4D).
SCD lipid products are enriched upon MSI1 expressionNext I sought to assay downstream effects of SCD regulation by MSI1 in cells.Because SCD plays an integral role in lipogenesis, it is reasonable to expect thatchanges in SCD activity would result in a shift in the cellular lipid profile. To thisend, I performed quantitative lipidomics mass spectrometry analysis. OPCproliferation halts upon MSI1 knockdown (Dobson et al. 2008). For this reason Iperformed these experiments in HEK293T cells with and without Msi1 expression. Iobserved statistically significant changes ranging from 2 to 32-­‐fold in 54 of the 312lipids assayed (FDR = 0.05, Figure 3.5A-­‐B). 50 of 54 significant data points displayedpositive changes, indicating that Msi1 expression stimulates production of certainlipids. 38 of the significantly changing lipids fell into one of three cholesterol andtriacylgylcerol (TAG) classes: cholesterol esters, 16:0 acyl-­‐containing TAG, and 16:1acyl-­‐containing TAG (Figure 3.5C-­‐D). Cholesterol esters and TAGs are made usingSCD products, and have been shown to be more abundant in mice overexpressing
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Figure 3.5: Lipidomics analysis of HEK293t cells ± MSI1 expression. Source data areincluded in Figure 6 source data 1. (A) Volcano plot of lipidomics data. Dashed linesdenote fold-­‐changes of ±1.5 and ±3. Red data points indicate lipids that aresignificantly changed upon Msi1 expression. (B) Scatter plot of lipidomics data. Dataare reported as nMoles per million cells. Red data points indicate lipids that aresignificantly changed upon Msi1 expression (FDR = 0.05). (C) Fold-­‐changes of thetotal cholesterol esters and two TAG classes in which 38 of the 54 significantlychanging lipids are categorized. Each class changes significantly with MSI1overexpression (P < 0.05). (D) Fold-­‐changes for the four lipids that comprise thetotal cholesterol esters class. All display significant changes with Msi1 expression(FDR = 0.05).
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SCD1, and less abundant in liver SCD1 knockout mice (Miyazaki et al. 2000; Attie etal. 2002). This indicates that SCD activity is upregulated in the presence of Msi1.Together, the binding data, co-­‐immunoprecipitation, western blots, and lipidomicsprofiling results show that stearoyl-­‐CoA desaturase expression is increased in thepresence of MSI1, possibly through direct association with consensus motifs in the3′ UTR of SCD transcripts.
Additional putative MSI1 regulatory targets involved in lipid metabolic processesThere are 2107 annotated 3′ UTRs for genes involved with lipids,cholesterols, fatty acid biosynthesis, and activity of the lipid-­‐responsivetranscription factor sterol responsive element binding protein (SREBP). Of these,1275 contain at least one MSI1 binding element. While the presence of a bindingelement does not confer regulation, MSI1 regulation of lipid metabolism may bemore complex than simple direct regulation of SCD. Indeed, a survey of 64 genesthat associate with MSI1 in a RIP-­‐ChIP experiment reveals that 8 are annotated to beinvolved with lipid metabolic processes (de Sousa Abreu et al. 2009).
DiscussionThe data presented in chapter II reveal that long chain ω-­‐9 fatty acidsbetween 18-­‐22 carbons in length are allosteric inhibitors of MSI1 RNA bindingactivity. In this chapter I present data implicating SCD, the enzyme that catalyzesthe ω-­‐9 desaturation, as a MSI1 regulatory target. The results are consistent with a
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model where MSI1 controls cellular proliferation through a feedback loop thatincludes SCD and its enzymatic products, such as oleic acid (Figure 3.6).Oleic acid is the precursor for synthesis of longer chain fatty acids such aseicosanoic, erucic, and nervonic acid, signaling molecules such as arachidonic acid,endocannabinoids, and prostaglandins, and membrane phospholipids. Oleic acid isabundant in the lipid-­‐rich myelin membranes produced by mature oligodendrocytes(Martinez and Mougan 1998), and CG4 OPCs show global changes in the lipid profileupon differentiation (Figure 3.1). OPCs express MSI1, but mature myelinatingoligodendrocytes do not (Dobson et al. 2008). In the oligodendrocyte lineage, oleicacid and MSI1 levels are anti-­‐correlated, which suggests a possible biological rolefor MSI1 inhibition by fatty acids (Martinez and Mougan 1998; Dobson et al. 2008).Another MSI1 inhibitor identified in the small molecule screen presented in chapterII is the PPARα agonist GW7647. PPARs are nuclear hormone receptor proteins thatregulate cellular processes including fatty acid metabolism, differentiation, cellcycling, and inflammation (Berger and Moller 2002). PPARγ agonists accelerateoligodendrocyte maturation (De Nuccio et al. 2011). Both GW7647 and oleic acidfunction as PPAR agonists, and both inhibit MSI1 RNA-­‐binding activity, suggestingthat MSI1 and PPARs possibly regulate gene expression in a reciprocal fashion.These data implicate the metabolic enzyme SCD as regulatory target of MSI1.The two human isoforms of SCD, SCD1 and SCD5, catalyze the conversion ofsaturated fatty acids (SFAs) into monounsaturated fatty acids (MUFAs) (Zhang et al.1999; Beiraghi et al. 2003; Minville-­‐Walz et al. 2010). MUFAs are then used in the
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Figure 3.6: Model of SCD regulation by MSI1, and subsequent downstreamconsequences of SCD activity changes.
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synthesis of numerous lipids, including phospholipids, di-­‐ and triacylglycerols,cholesterol esters, and signaling molecules such as eicosanoids. SCD is therefore anessential enzyme to normal cellular proliferation, metabolism, and signaling. It isalso possible that MSI1 may also be regulating other factors involved in lipid, fattyacid and cholesterol metabolism. The Penalva group identified 64 putative MSI1targets using a RIP-­‐ChIP analysis in HEK293T cells (de Sousa Abreu et al. 2009). Ofthese putative targets, eight are annotated to play a role in lipid, fatty acid orcholesterol metabolic processes. These include three variants of the fatty acidelongase ELOVL5, two variants of the glycolipid biosynthetic factor PIGF, twovariants of Lamin B receptor (LBR), and aminoadipate-­‐semialdehydedehydrogenase-­‐phosphopantetheinyl transferase (AASDHPPT).SCD has been implicated in a number of disease states, including obesity,diabetes, hyperlipidemia, and cancer. Obese and diabetic animals produceabnormally high levels of TAGs and cholesterol esters (Coleman and Lee 2004).These energy storage molecules are also elevated in a hyperlipidemia mouse modelthat overexpresses SCD (Attie et al. 2002). Conversely, SCD1 knockout mice displayimpaired biosynthesis of both TAGs and cholesterol esters (Miyazaki et al. 2000).SCD is upregulated in tumor cells, including colonic and esophageal carcinoma (Li etal. 1994). Cancerous cells use newly synthesized lipids primarily for phospholipidproduction, which are used in new membranes (Swinnen et al. 2000). Additionally,new evidence suggests that SCD1 activates the oncogenic Akt and AMPK signalingpathways (Scaglia and Igal 2008; Scaglia et al. 2009).
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SCD regulates SFA and MUFA homeostasis and therefore plays an integralrole in lipid signaling pathways. SFAs serve as proinflammatory factors by acting asligands for immune receptors such as those in the Toll-­‐like receptor family (Shi et al.2006; Nguyen et al. 2007). MUFA products of SCD are further modified to becomepolyunsaturated fatty acids, such as arachidonic acid, which are converted intoeicosanoids by cyclooxygenases (James et al. 2000). Eicosanoids serve asproinflammatory and immune signaling molecules (Liu et al. 2011). Recent data alsolinks SCD to Wnt signaling through mediation of the palmitic/palmitoleic acidconversion, as active Wnt proteins require conjugation of palmitoleic acid (Rios-­‐Esteves and Resh 2013). The balance between SFAs and MUFAs must be tightlycontrolled, and while SCD is not the only enzyme involved in the process, it doesserve as an essential gatekeeper in the conversion of dietary SFA to MUFA.Several examples of functional interactions between transcription factorsand fatty acids have been published. For example, fatty acids associate withmembrane-­‐bound SREBP to inhibit a cleavage event that produces the activatedform of SREBP, a transcription factor involved in lipid homeostasis (Wang et al.1994). Free fatty acids have been shown to stimulate proinflammatory cytokineexpression while decreasing anti-­‐inflammatory cytokine expression in adipocytes(Bradley et al. 2008). Interestingly, treatment of various tumor lines with oleic acidresults in transcriptional inhibition of the Her-­‐2/neu (erbB-­‐2) oncogene throughPEA3, although the precise mechanism of regulation remains unknown (Menendezet al. 2006). In yeast cells, fatty acids bind oleate-­‐activated transcription factors
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(OAFs) to effect transcription of genes responsible for fatty acid metabolism, glucosemetabolism, stress response, and other related processes (Gurvitz andRottensteiner 2006). Although numerous transcription factors are regulated by fattyacids, MSI1 is the first example of a fatty acid-­‐responsive RNA binding protein.Integration of metabolite sensing and post-­‐transcriptional regulation iswidespread in bacteria, but comparatively few examples have been found ineukaryotes (Winkler and Breaker 2003; Roth and Breaker 2009). Riboswitchesregulate gene expression at the RNA level in response to intermediary metabolites.Small molecule metabolites bind mRNA transcripts, usually in the 5′ UTR, to inducea structural change that interferes with the transcriptional or translationalmachinery (Winkler and Breaker 2005). In bacteria, riboswitches sensitive to anumber of metabolites have been characterized, including guanine, adenine,coenzyme B12, glycine, lysine, and thiamine pyrophosphate (TPP), among others(Grundy et al. 2003; Mandal et al. 2003; Sudarsan et al. 2003; Vitreschak et al. 2003;Mandal and Breaker 2004; Mandal et al. 2004). Although most riboswitches havebeen identified within the bacterial mRNA 5′ UTR, TPP riboswitches, have also beenidentified in plants and fungi (Kubodera et al. 2003; Sudarsan et al. 2003). Whileriboswitches comprise an essential cis-­‐regulatory mechanism in bacteria, othermechanisms of coupling metabolic state to post-­‐transcriptional gene regulation mayoccur in eukaryotes.An increasing number of protein-­‐metabolite-­‐RNA interactions have nowbeen identified in bacteria and eukaryotes. One example is the bacillus subtilis
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tryptophan RNA-­‐binding attenuation protein (TRAP). Increasing intracellulartryptophan levels induce TRAP multimerization, which enables mRNA recognitionand subsequent translational repression of targets (Gollnick et al. 1990; Antson etal. 1995; Babitzke et al. 1995; Yakhnin et al. 2004). Intriguingly, several metabolicenzymes have been proposed to “moonlight” as RNA-­‐binding proteins in “RNA /Enzyme / Metabolite (REM)” networks (Ciesla 2006; Hentze and Preiss 2010;Castello et al. 2012). A notable example is cytosolic aconitase, which demonstratesmutually exclusive enzymatic and RNA-­‐binding functionality, depending uponcellular iron levels (Hentze and Argos 1991; Rouault et al. 1991). A number ofmetabolite-­‐sensitive enzymes have also demonstrated RNA-­‐binding activity,including GAPDH, glutamate dehydrogenase, thymidylate synthase, anddihydrofolate reductase (Ryazanov 1985; Chu et al. 1991; Chu et al. 1993; Preiss etal. 1993; Dollenmaier and Weitz 2003). This growing body of research suggests thatmetabolite-­‐mediated post-­‐transcriptional regulation is much more prevalent thanpreviously thought.The results presented here show that MSI1 N-­‐terminal RRM1 acts as ametabolite sensor, the first example of such activity observed for the most abundantRNA-­‐binding motif in eukaryotic genomes. A survey of RRM structures in theprotein data bank reveals several with a surface cavity on the alpha helical face,which may comprise metabolite-­‐binding pockets. I predict that a network of RNAregulatory proteins act as metabolite sensors, possibly replacing the bacterialriboswitch regulation that appears to have been largely lost in eukaryotes.
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Methods
PlasmidsDNA encoding the mouse Msi1 RNA binding domain fragment (amino acids 7-­‐192)was amplified from the mammalian gene collection (MGC) full-­‐length ORF clone100014969 (Invitrogen) using gene specific primers (forward primer: 5′-­‐cgcgcggatcccagcccggcctcgcctcccc-­‐3′; reverse primer: 5′-­‐gcgcgaagcttcggggacatcacctcctttg-­‐3′). This fragment was digested using BamHI andHindIII restriction enzymes and subcloned into a modified version of pET-­‐22bvector (Invitrogen) in which the pelB leader sequence was replaced with a His6-­‐Glytag followed by a TEV protease site to make pET-­‐22HT-­‐MSI1 (7-­‐192).
Purification of recombinant proteinsH6-­‐TEV-­‐MSI-­‐1 (7-­‐192) was expressed and purified from Escherichia Coli BL21(DE3)cells. Liquid cultures grown at 37ºC were induced for 3 hours during mid-­‐log phasewith 1 mM Isopropyl β-­‐D-­‐1-­‐thiogalactopyranoside (IPTG). Cells were pelleted,resuspended in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM Imidazole, 5mM β-­‐Mercaptoethanol (BME)), and lysed using a microfluidizer (IDEX Health andScience). Soluble lysate was applied to a Ni-­‐NTA column (Qiagen), washed withwash buffer (50 mM NaH2PO4, 300 mM NaCl, 50 mM Imidazole, 5 mM BME), andeluted with elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM Imidazole, 5 mMBME). Fractions were analyzed by SDS-­‐page and those containing recombinant MSI1
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or MSI2 were pooled and dialyzed overnight into S buffer (50 mMMOPS pH 6.0, 20mM NaCl, 2 mM DTT). Pooled fractions were applied to a HiTrap SP cation exchangecolumn (GE Healthcare) and eluted using a gradient of 0.1M to 1 M NaCl in S Buffer.Fractions containing MSI1 or MSI2 were pooled and dialyzed overnight into Q buffer(50 mM Tris pH 8.8, 20 mM NaCl, 2 mM DTT) prior to loading a HiTrap Q anionexchange column (GE Healthcare). The protein was eluted over a gradient from 0.1to 1 M NaCl in Q buffer. Fractions containing MSI were pooled and dialyzed usingSpectra/Por 7 25 kD (MSI1) or 10 kD (MSI2) molecular weight cutoff tubing(Spectrum laboratories) overnight into storage buffer (50 mM Tris pH 8.0, 20 mMNaCl, 2 mM DTT). The yield of >95% pure MSI1 or MSI2 is typically 20 mg per literof culture (Figure 2.1).
RNA sequences and labelingSynthetic RNA oligonucleotides were ordered from IDT and 3′ end-­‐labeled withfluorescein 5-­‐thiosemicarbazide (Invitrogen) according to the method of Reines andCantor (Reines and Cantor 1974; Pagano et al. 2007; Farley et al. 2008). Briefly,5x10-­‐10 mol of RNA were incubated with 100 mM NaOAc, pH 5.1 and 5 nmol ofNaIO4 for 90 minutes at room temperature then ethanol precipitated. The RNA wasresuspended in 50 µl of 1 mM fluorescein-­‐5-­‐thiosemicarbazide in 100 mM NaOAc,pH 5.1. After incubating overnight at 4 °C, the RNA was separated from unreactedlabel by ethanol precipitation and subsequently passaged through a Piercecentrifuge column packed with Spehadex G-­‐25 resin (GE Healthcare).
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Fluorescence polarization and electrophoretic mobility shift assaysFluorescence polarization (FP), also known as fluorescence anisotropy, andFluorescence electrophoretic mobility shift assays (F-­‐EMSA) were used to measurethe binding affinity of recombinant MSI1 to fluorescein-­‐labeled RNA aptamers.Assays were conducted as described in Pagano, et al. (Pagano et al. 2011). Briefly, 2nM fluorescein-­‐labeled RNA was incubated with varying concentrations ofrecombinant purified MSI1 protein in equilibration buffer (37.5 mM Tris pH 8.0, 75mM NaCl, 0.0075% igepal, 0.0075 mg/mL tRNA) for three hours. Fluorescencepolarization was determined with a Victor V3 plate reader using a 480 ± 31 nmexcitation filter and a 535 ± 40 nm emission filter. After measuring FP, the sampleswere mixed with 6x bromocresol green loading dye (0.15% (w/v) Bromocresolgreen, 30% (v/v) glycerol) and run on a 5% native polyacrylamide gel at 120V for75 minutes at 4ºC. Wet gels were scanned with a Typhoon FLA 9000 Biomolecularimager (GE healthcare) using a 473 nm laser and a long-­‐pass cut-­‐off filter (510 nm).The fraction of bound RNA was determined by quantifying lower (free) and upper(bound) band intensities using MultiGauge and ImageGauge software (Fujifilm). ForRNA sequences with two shifted species, the bands were quantified together.Polarization values or the fraction of bound RNA were plotted as a functionof protein concentration and fit to the Hill equation (1) to determine the apparentdissociation constant (Kd) and the apparent Hill coefficient (n). The upper (m) andlower (b) values were also fit in order to define the assay window.
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Cell-­‐based experiments
Cell lines and cultureCG-­‐4 rat oligodendrocyte progenitor and B104 neuroblastoma cells were a gift fromLynn Hudson and were cultured as previously described (Louis et al. 1992). CG-­‐4cells were maintained in the progenitor state in 30% B104 conditioned media.HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen)with 10% fetal bovine serum (Atlanta Biologicals Inc., Lawrenceville, GA), 100units/ml penicillin, and 100 µg/ml streptomycin (Invitrogen).
Proliferation assays100,000 HEK293T or CG-­‐4 cells were seeded into each well of 6-­‐well culture plates.24 h after seeding, cells were treated with either 50 µM oleic acid in EtOH or EtOHonly as a control. 24, 48, and 72 h after fatty acid treatment, cells were assayed forproliferative changes using the Cyquant direct cell proliferation assay (Invitrogen)according to the manufacturers instructions using a Victor V3 plate reader(PerkinElmer). The treatment concentration was chosen after a dose response fortoxicity and efficacy across a range defined by established protocols forneuroblastoma cells (Figure 3.2A) (Di Loreto et al. 2007).
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RNA co-­‐immunoprecipitationFor each experiment, 106 CG-­‐4 cells were crosslinked for 10 minutes with 0.1%formaldehyde in PBS then scraped into lysis buffer (1% (w/v) SDS, 10 mM EDTA, 1xEDTA-­‐free protease inhibitors). Lysate was diluted in 10X IP buffer (0.01% SDS,1.1% Triton X-­‐100, 1.2 mM EDTA, 16.7 mM Tris-­‐HCl, pH 8.1, 167 mM NaCl) with 8units SUPERase-­‐In (Ambion). Immunoprecipitation was performed using rabbitpolyclonal anti-­‐Musashi 1 (Abcam ab21628) or rabbit polyclonal anti-­‐GFAP (Abcamab7260) conjugated to Dynabeads protein G (Invitrogen) according to themanufacturer’s instructions. After proteinase K digestion (NEB) and heat-­‐inducedcrosslink reversal, RNA was phenol-­‐chloroform extracted, ethanol precipitated andresuspended in 20 µL nuclease-­‐free water. RNA was then treated with DNase(Ambion Turbo DNAfree) to remove any DNA contamination. RNA was reversetranscribed and amplified using a SuperScript® III One-­‐Step RT-­‐PCR System withPlatinum®Taq (Invitrogen) and transcript-­‐specific fluorescein-­‐labeled primers for
scd1 and numb. PCR products were separated from free primers on a 5% nativepolyacrylamide gel, imaged on a Fuji FLA-­‐5000 imager, and quantified using ImageGauge software.
MSI1 overexpression and qRT-­‐PCRTwenty four hours prior to transfection, 106 HEK293T cells were seeded in 10 cmculture plates. Cells were transfected with 2 µg pCDH-­‐CMV-­‐MSI1(FL) or empty
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pCDH-­‐CMV-­‐MCS-­‐EF1-­‐Puro using Effectine reagent according the manufacturersinstructions (Qiagen). 24 h after transfection, transfected cells were selected forwith 2 µg/mL puromycin (Sigma). RNA and protein was harvested 72 h aftertransfection. To confirm MSI1 overexpression, RNA was collected using Trizolreagent (Invitrogen) followed by DNAse treatment (Turbo DNAfree, Ambion)according to the provided instructions. RNA yield was determined byspectrophotometry and quantitative RT-­‐PCR was performed with an Opticonthermal cycler (Bio-­‐Rad) using an iScript One-­‐Step RT-­‐PCR Kit with SYBR Green(Bio-­‐Rad) according to the manufacturer’s instructions. All assays were performedin triplicate. Data were analyzed by sigmoidal curve fitting according to the methodof Rutledge (Rutledge 2004) and normalized to GTF2i or Tubulin.
SCD western blotsCells were lysed with SDS lysis buffer (1% SDS, 10 mM EDTA, 1x EDTA-­‐free proteaseinhibitors) and protein concentration was determined by the bicinchoninic acidassay method (BCA, Pierce) according to the manufacturer protocol. Samples wereboiled for 5 minutes after the addition of 6x Laemmli buffer (9% SDS and 60%glycerol, 375 mM Tris-­‐HCl pH 6.8, 0.015% Bromophenol blue, 12% β-­‐mercaptoethanol). Proteins were separated for 2 h on a 12% SDS-­‐polyacrylamidegel using a Bio-­‐Rad mini-­‐PROTEAN electrophoresis apparatus, transferred to low-­‐fluorescence PVDF membranes (Millipore) for 2 h at 4ºC at a constant 70 V in 25mM Tris, 150 mM glycine, and 10% (v/v) methanol transfer buffer, blocked with
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Odyssey Blocking Buffer (OBB, LI-­‐COR Biosciences) for 1 h at room temperature,and probed with 1:1000 dilution of mouse monoclonal anti-­‐SCD antibody (Abcamab19862) in OBB overnight at 4ºC. After washing with PBS-­‐T, membranes wereincubated with fluorescent goat anti-­‐mouse secondary antibodies (LI-­‐CORBiosciences, 926-­‐32210) at 1:15000 in OBB for 1 h at room temperature. Signal wasdetected using an Odyssey Infrared Imaging System (LI-­‐COR Biosciences). To ensureantibody specificity, shRNA knockdown of SCD1 was performed with twoindependent shRNA constructs (Open Biosystems V3LHS_305870 andV3LHS_305872) and compared with non-­‐silencing shRNA construct (OpenBiosystems RHS4346).
Total lipid extractionCells were removed from plates with 0.25% Trypsin-­‐EDTA (Gibco) and the total cellnumber was obtained using a hemocytometer. Each sample contained 1-­‐2x106 cells.After pelleting by centrifugation, cells were resuspended in 200 µL H20, immediatelyfollowed by 250 µL methanol and 125 µL chloroform/0.01% Butylatedhydroxytoluene (BHT). Samples were shaken vigorously for 30 seconds, then anadditional 250 µL chloroform/0.01% BHT and 250 µL H20 was added. After 30seconds of additional shaking, samples were centrifuged for 5 minutes at 4º C. Thechloroform layer was removed to a new tube, and the cell sample was treated with250 µL of chloroform/0.01% BHT, vigorous shaking, centrifuging and subsequentchloroform layer removal twice more. Combined chloroform layers were washed
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with 500 µL KCL, then 500 µL H2O. Insoluble layers were transferred to glass vialsand dried under argon. Samples were sent to the Kansas lipidomics research centerfor analysis by mass spectrometry as previously described (Welti et al. 2002). 5independent biological replicates were analyzed for each treatment group. SeeAppendix I.
Lipidomics data analysisThe lipid profile data were acquired at Kansas Lipidomics Research Center (KLRC).Instrument acquisition and method development at KLRC was supported by NSFgrants MCB 0455318, MCB 0920663, DBI 0521587, DBI 1228622, Kansas INBRE(NIH Grant P20 RR16475 from the INBRE program of the National Center forResearch Resources), NSF EPSCoR grant EPS-­‐0236913, Kansas TechnologyEnterprise Corporation, and Kansas State University. Lipidomics data were reportedas nMoles / 1x106 cells. After removing data points for samples with values belowthe limit of detection for the instrumentation (0.02 nMoles / 1x106 cells), all datapoints for which no signal was detected in either treatment group were removed. Apseudocount of 0.002 nMoles / 1x106 cells was added to all remaining data points.Outliers were eliminated using a Q test. Significant differences between treatmentsfor each lipid class were determined using a Student’s t-­‐test and an FDR of 0.05. SeeAppendix I.
Critical micelle concentration determination
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The critical micelle concentration (CMC) for oleic acid in equilibration buffer wasdetermined using N-­‐phenyl-­‐1-­‐naphthylamine (NPN), a compound that fluoresceswhen sequestered into micelles (Hagihara et al. 2002; Hasegawa et al. 2008). 25 µMNPN was incubated with varying amounts of oleic acid for 30 minutes. Fluorescenceintensity was determined with a Victor V3 plate reader using a 355 nm excitationfilter and a 460 nm emission filter. Fluorescence intensity data were plotted as afunction of fatty acid concentration. The CMC was determined by a two statesegmented linear regression to identify the breakpoint between baselinefluorescence and fluorescence caused by NPN association with micelles.
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Chapter 4: Concluding remarks and future directions
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The initial goal of the research presented here was to identify a smallmolecule inhibitor of the RNA-­‐binding protein MSI1. The small molecule screen andsubsequent characterization reveal that the intermediary metabolite oleic acidinhibits MSI1 RNA-­‐binding activity. Additionally, I identified a novel putative MSI1target, stearoyl-­‐CoA desaturase (SCD), which couples MSI1 to metabolic regulationof lipid production in proliferating and differentiating cells. However, I am left witha number of questions both biochemical and biological in nature. The mechanism ofregulation is not yet completely defined, and the structure of the bound complexremains unsolved. Additionally, the biological significance of a regulatory feedbackloop between MSI1 and SCD is not yet understood, and we have not yetcharacterized any additional natural fatty acid derivatives that may inhibit MSI1activity in cells.
Biochemical characterization of Musashi-­‐1 inhibition
18-­‐22 carbon ω-­‐9 fatty acids inhibit MSI1 RNA-­‐binding activityThe inhibitor screen reported here consisted of over 30,000 compoundsacross two libraries. 4 potential inhibitors were confirmed through secondaryscreening FP and F-­‐EMSA assays. Of these, two were of biological interest – GW7647and oleic acid -­‐ because they both activate PPAR nuclear hormone proteins, whichare metabolically regulated transcription factors. GW7647 was not a particularlystrong inhibitor. Oleic acid was a better inhibitor, as determined by its Ki, and isabundant in myelin, which is produced by mature oligodendrocyte cells in the
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central nervous system. MSI1 is abundant in oligodendrocyte progenitor cells, butnot in mature myelinating oligodendrocytes. It was therefore conceivable that asoleic acid levels rise during differentiation, oleic acid could be acting to turn off MSI1function during the transition to maturity.A survey of fatty acids and fatty acid derivatives revealed that a number ofstructural features are important for inhibition. Modification of the carboxylate isnot tolerated, indicating that the charge and/or size of that group is important.Altering the number of carbons between the double bond and the omega end of thefatty acid molecule reduced inhibition, which indicates a length requirement for theomega tail. Finally, changing the orientation or saturating the cis double bondeliminates inhibition, indicating that a kink in the fatty acid structure is essential forinhibitory function. The list of fatty acids tested was not exhaustive, so it is possiblethat some unidentified modifications to the fatty acid would be tolerated.Oleoyl-­‐CoA and erucyl-­‐CoA are abundant and soluble in cells, so I sought totest whether these molecules are effective inhibitors. Oleoyl-­‐CoA and erucyl-­‐CoAboth inhibited MSI1 RNA-­‐binding activity, but thin layer chromatography revealedthe stocks contained some free oleic acid and erucic acid. I therefore could not ruleout the possibility that inhibition was due to association with the free fatty acid.Other derivatives that should be tested include 2-­‐hydroxy oleic acid (2OHOA) andIloprost. 2OHOA is in clinical trials as an anti-­‐cancer drug for cancers of theepithelial and neural lineage (Teres et al. 2012). Preliminary results indicate thatglioma tumors treated with 2OHOA show decreased proliferation and increased
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differentiation (Teres et al. 2012). An additional hydroxyl at C2 may evenstrengthen the electrostatic properties of the carboxylate group. Iloprost is aprostaglandin I2 analog that has been shown to induce differentiation inoligodendrocyte progenitor cells (Takahashi et al. 2013). Structurally, it is less clearhow Iloprost might associate with MSI1, but it is a fatty acid derivative and knowingwhether or not it inhibits MSI1 will add to our understanding of the mechanism ofinhibition. Finally, endocannabinoids and eicosanoids are signaling moleculesderived from fatty acids that play an essential role in brain and organ development.While there are many molecules that fall into these classes, strategic testing shouldbe conducted to determine if they have Msi1 inhibitory properties.
A model for the mechanism of inhibitionBiochemical and biophysical characterization of the association betweenMSI1 and oleic acid revealed a model for the mechanism of inhibition. There is ahydrophobic binding pocket located on the alpha-­‐helical face of RRM1. This bindingpocket is evolutionarily conserved in all MSI family proteins for which structureshave been solved. The sequence of RRM1 is highly conserved among all MSI familyproteins, which indicates that the binding pocket structure is likely also conserved.Modeling studies suggest that oleic acid docking with this binding pocket isthermodynamically favorable. The double bond allows 18-­‐22 carbon ω-­‐9 fatty acidsto bend around MSI1 to enable interaction of the carboxylate group with one of
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several basic residues on the flexible loop region connecting the alpha helical andbeta sheet faces of RRM1.The structure-­‐activity relationship studies support this model, asmodification of the carboxylate, omega-­‐end length, or presence/orientation of thedouble bond are not tolerated. Circular dichroism and tryptophan fluorescenceexperiments indicate that inhibition occurs through direct interaction of MSI1 withthe fatty acid, which induces a change in the secondary structure of the protein.Analytical ultracentrifugation indicates that the majority of the protein remainsmonomeric, ruling out apparent inhibition by aggregation or oligomerization ofprotein.Attempts to solve the oleic acid-­‐bound MSI1 structure by NMR wereunsuccessful. The protein behaves well for NMR, and has been used in NRM studiespreviously (Kurihara et al. 1997; Nagata et al. 1999; Miyanoiri et al. 2003; Ohyamaet al. 2011). However the CMC of oleic acid in our buffer system is 75 µM, whichprecludes use in NMR because concentrations must be higher to obtain a saturatedbinding spectrum at good resolution. We did observe peak broadening and signalloss upon oleic acid titration, with the greatest signal losses mapping to key residuesin the areas predicted to bind oleic acid in our docked model. These include W29,Q30, L36, C49, L50, R53, S60, G62, V74, T89, K98, which are computationallypredicted to either interact directly or undergo a structural change upon oleic acidassociation. The observed loss of intensity is likely due to protein precipitation in
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the presence of high concentrations of oleic acid, association with oleic acid micelles,or a combination of the two.To obtain a bound structure, it would be interesting to attempt an NMRmethod using detergents that have been used previously to solve structures withinsoluble ligands and/or proteins. These detergents create a non-­‐reactive micellarenvironment in which the protein/ligand can be suspended. For instance, thedetergent (2H38)dodecylphosphocholine (DCP) has been used to study thestructures of several insoluble membrane proteins in NMR studies. There are anumber of additional detergents that can also be screened for appropriate NMRconditions. It would be worth trying some of these techniques, as a bound structurewould enable detailed mechanistic study and development of inhibitor derivativesand protein mutants to separate RNA-­‐binding from oleic acid-­‐binding functionality.To further probe the mechanism of inhibition in lieu of a bound NMRstructure, Francesca Massi used molecular dynamics simulations to investigate theprobable structural changes that MSI1 undergoes upon oleic acid binding. Herresults further support a model in which oleic acid binds to the alpha helical face ofMSI1 RRM1, but indicate a surprising amount of flexibility and structuralreorganization when oleic acid is bound. This simulation indicates that residuesinvolved in RNA binding are pulled away from the RNA-­‐binding beta sheet face.Many of these demonstrated signal intensity loss in the NMR titration of oleic acid,which supports the molecular dynamics simulation prediction that they may beundergoing a structural change.
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Mutational analysis of several residues predicted to be important for oleicacid binding further supports the computational model and simulation. Residuesthat surround the opening (G35) and comprise the hydrophobic pocket (G64 andH83) on the alpha helical face are important for fatty acid inhibition. Additionally,residues predicted to interact with the carboxylate of the inhibitory fatty acids (R53and R61) are also required to maintain inhibition. Further mutational analysis willbe required to identify a separation-­‐of-­‐function mutant MSI1 that maintains RNA-­‐binding ability but is immune to the inhibitory activity of 18-­‐22 carbon ω-­‐9unsaturated fatty acids. A true separation-­‐of-­‐function mutant will enable in-­‐vivoexperimentation to determine whether fatty acids are regulating Msi1 in cells.Generating such a mutant will likely be accomplished through multiple strategicmutations that preserve RNA-­‐binding structural properties but perturb thestructural properties that allow oleic acid association. A high-­‐resolution NMRstructure of oleic acid bound to MSI1 will undoubtedly help guide mutational effortsby illuminating the interactions that stabilize fatty acid binding.
Biological characterization of Musashi-­‐1 inhibition
A model for MSI1 in proliferationMSI1 has been implicated as a cellular proliferation factor in both healthyand cancerous cells of neural and epithelial lineages. Overexpressing MSI1 preventsdifferentiation, while knockdown results in decreased proliferation and increasedrates of apoptosis in both healthy and tumorous cells. The biochemical results
150
presented here indicate that MSI1 is inhibited by a specific class of fatty acids thatare abundant in proliferating cells and in oligodendrocytes, which are a specializedtype of differentiated non-­‐proliferative cell.Treatment of MSI1-­‐expressing oligodendrocyte progenitor cells with oleicacid results in decreased proliferation, while treatment with non-­‐inhibitory stearicacid does not decrease proliferation. HEK cells, which do not express MSI1, respondto neither oleic acid nor stearic acid treatment. While these data do not demonstratethat MSI1 is inhibited by oleic acid in cells, the phenotype is in agreement with thatof MSI1 knockdown in oligodendrocyte progenitor cells by RNAi. These experimentsshould be repeated in a HEK background with a mutant form of MSI1 that isunresponsive to fatty acid inhibitors. Luciferase reporters that contain the 3′ UTR ofa MSI1-­‐responsive gene, such as Numb, would provide more convincing data todetermine whether fatty acids are directly inhibiting MSI1 regulatory activity.The data presented here also indicate that MSI1 positively regulates SCD, theenzyme that produces ω-­‐9 unsaturated fatty acids by inserting a double bond in 16and 18 carbon saturated fatty acids. Stearic acid is the most prevalent substrate ofSCD, and the product of stearic acid desaturations is oleic acid. Oleic acid can bemodified into longer-­‐chain fatty acids and/or incorporated into phospholipids formembranes, energy storage molecules such as cholesterol esters andtriacylgylcerols, or further desaturated into polyunsaturated fatty acids for signalingmolecules.
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Lipidomics analysis of MSI1-­‐expressing HEK293T cells indicates thatdownstream products of SCD are specifically upregulated. These are predominantlycholesterol esters and triacylgylcerols, both of which are more abundant in miceoverexpressing SCD1 and less abundant in liver SCD1 knockout mice. Cholesterolesters and triacylgylcerols are energy storage molecules essential in highlyproliferative cells. Interestingly, cancerous cells display elevated SCD expression,and SCD knockdown results in decreased proliferation and increased apoptosis – apattern startlingly similar to that of MSI1.Together, the data presented here indicate a model in which MSI1 and SCDexist in a feedback loop to maintain homeostasis of proliferative epithelial andneural progenitor cells (Figure 4.1). Loss of homeostasis could contribute to theincreased proliferation observed in tumors with increased MSI1 and/or SCDabundance. There are two obvious scenarios for this loss of homeostasis. 1) Loss ofMSI1/SCD homeostasis drives tumorigenesis: MSI1 may be positively regulated byan unknown factor, resulting in positive regulation of SCD and therefore increasedproduction of ω-­‐9 unsaturated fatty acids. Assuming MSI1 is abundant enough, theincrease in unsaturated fatty acid concentration might be insufficient to inhibit MSI1and restore homeostasis. 2) Loss of MSI1/SCD homeostasis is a by-­‐product oftumorigenesis: The machinery that incorporates ω-­‐9 unsaturated fatty acids intomembranes, energy storage, and signaling molecules might be more active, therebyrelieving feedback inhibition of MSI1 activity and subsequently stimulating SCD
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Figure 4.1: Model of MSI1/SCD homeostasis in normal, proliferative cells.
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expression. This scenario would likely occur in cancerous cells where proliferativechecks and balances have already been disrupted.Understanding whether MSI1 is driving or reacting to tumorigenesis will bean essential step in characterizing its role in cancer. To date, no direct regulators ofMSI1 expression have been identified, but there is some evidence for their existence.In colorectal tumors, MSI1 expression is upregulated upon NOTCH3 stimulation, andinhibition of NOTCH3 signalling results in elevated levels of NUMB, a protein that isnormally translationally repressed by MSI1 (Pasto et al. 2014). Additionally, theabsence of MSI1 protein in mature neural and epithelial cells indicates thattranscription and/or translation are being repressed.Identification of candidate transcriptional and post-­‐transcriptionalregulators, while not trivial, can be accomplished using the growing body ofsequencing data. We can use genomic information to identify potential transcriptionfactor and post-­‐transcriptional regulatory factor binding sites. Depending upon thecandidate regulatory factor, data sets may be available to elucidate their bindingtargets, gene expression changes upon knockdown, or the ribosome profile changesupon knockdown. Candidate targets can also be tested in vitro using biochemicalbinding assays and in vivo using reporter assays. To design efficient and effectiveanti-­‐cancer therapies, we must first understand the pathways that lead totumorigenesis. MSI1 may be a good therapeutic target regardless of whether it is
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driving or supporting tumorigenesis, but we ultimately must understand whether itplays a driving or supporting role in tumorigenesis.
A model for MSI1 in oligodendrocyte differentiationMSI1 is required for proper neural development. MSI1 knockout mice displayabnormal brain development, and embryonic neurospheres cultured from thesemice display fewer mature cell types (Sakakibara et al. 2002). MSI1 depletion inOPCs results in differentiation, reduced proliferation, and increased apoptosis(Dobson et al. 2008). Only two MSI1 regulatory targets have been characterized inmammalian neural tissue, although recent RIP ChIP studies have identified newputative targets that require in vitro and in vivo characterization. MSI1translationally represses Numb, an inhibitor of NOTCH signaling, and P21WAF1, a cellcycling inhibitor. Repression of these targets by MSI1 may be involved in preventingoligodendrocyte progenitor cell differentiation, but the regulatory mechanismsgoverning MSI1 expression levels remain unknown.This research supports a novel hypothesis for the regulation of MSI1 levels inoligodendrocyte progenitor cells. 18-­‐22 carbon ω-­‐9 unsaturated fatty acids are themost abundant fatty acids in the myelin membrane produced by matureoligodendrocytes. MSI1 is expressed in oligodendrocyte progenitor cells, but not inmature, myelinating oligodendrocytes. However, the MacNicol lab has shown thatMSI1 protein may linger during differentiation, indicating a need to inactivate theexisting active protein (MacNicol et al. 2008). The data herein indicate that MSI1
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Figure 4.2: Model of MSI1 homeostasis in normal in OPCs.
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may be inactivated by the same fatty acids that become abundant as thedifferentiating cells prepare to produce myelin.This hypothesis proposes a “switch” mechanism to drive differentiation, butagain, there may be two scenarios in which the “switch” is flipped, depending uponwhether MSI1 expression is turned off to help initiate differentiation, or as a resultof differentiation (Figure 4.2). 1) Oleic acid levels in proliferating progenitor cellsmay serve to prevent over-­‐activity of MSI1, thereby maintaining proliferationhomeostasis. If MSI1 is downregulated in preparation for differentiation, the switchwould be flipped, enabling the existing free fatty acids to inactivate the remainingMSI1 protein so differentiation can proceed. This scenario assumes that MSI1expression is turned off as differentiation is initiated. 2) Oleic acid levels may beincreased in preparation for differentiation, thereby flipping the switch andinactivating existing MSI1 protein. This model assumes that MSI1 expression isturned off after the differentiation machinery is activated.Testing these models is difficult with existing technology. Cell samples wouldneed to be precisely staged, using fluorescent markers for progenitor cells (A2B5and O4) and mature oligodendrocytes (MBP and O1) Immature oligodendrocytesthat are undergoing the transition may be positive for both markers. Lipidomicsmass spectrometry analysis will reveal how the lipid profile changes at each stage,indicating whether fatty acid levels increase during of after differentiation. qRT-­‐PCRandWestern blot analysis will reveal how the MSI1 expression profile changes ateach stage, indicating whether MSI1 RNA and protein levels decrease during or after
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the transition. Acquiring enough cellular material, especially for the differentiatedoligodendrocyte population, will prove challenging. Additionally, lipidomics analysiswill not provide a sensitive reading for free fatty acids, but the downstreamproducts can be a good indicator of fatty acid levels in cells.
Metabolic regulationChanges in metabolic state induce compensatory changes in gene expression.In Eukaryotes, transcriptional control of gene expression in response to metabolicchanges has been widely studied. Metabolites including fatty acids, vitamins,alcohols, amino acids, and nucleotides and derivatives are known to regulatetranscription. It is surprising that more is not known about the effect thatintermediary metabolites have on post-­‐transcriptional regulation.In the introduction I highlighted several examples of post-­‐transcriptionalmechanisms that respond to intermediary metabolites. These examples mayrepresent unique, non-­‐pervasive mechanisms of post-­‐transcriptional regulation.However, it is likely that new systems-­‐level approaches will identify additionalexamples. If metabolic control of post-­‐transcriptional regulation is indeedwidespread in eukaryotes as it is in bacteria, there will be broad implications for thedevelopment of novel therapeutics that target metabolite sensitive RNA-­‐bindingproteins involved in disease processes. The Musashi-­‐1/fatty acid/SCD feedback loopdescribed here may provide the necessary link to spur additional research into post-­‐transcriptional regulation of metabolic processes.
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Appendix 1: Lipidomics protocol and data analysis
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Note: I recommend contacting the Kansas Lipidomics Research Center (KLRC) todiscuss your application. The director and lab manager were extremely helpful.They provided suggestions for experimental design, suggested application-­‐specificsample preparation techniques, and assisted with the data analysis.
Total lipid extraction and preparation for lipidomics analysis
1) Prepare and treat cells – must prepare at least 5 plates/flasks per treatment for 
proper statistical analysis. 
2) Collect cells from plates or flasks. 
a. Use preferred method, such as 0.25% Trypsin-EDTA (Gibco) 
3) Count total cell number from each plate using a hemocytometer.  
4) Loosely pellet cells (800xG  for 2 minutes) and aspirate media. 
5) Resuspend pellet in 200 µL H20 per 1-2x106 cells.  
6) Add 250 µL methanol and 125 µL chloroform/0.01% Butylated hydroxytoluene 
(BHT).  
7) Shake samples vigorously for 30 seconds.  
8) Add an additional 250 µL chloroform/0.01% BHT and 250 µL H20.  
9) Shake samples vigorously for 30 seconds.  
10) Centrifuge for 5 minutes at 4º C at maximum speed.  
11)  Remove the chloroform layer and transfer it to a new tube. 
12)  Add an additional 250 µL of chloroform/0.01% BHT to the cell lysate tubes. 
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13)  Shake samples vigorously for 30 seconds.  
14)  Centrifuge for 5 minutes at 4º C at maximum speed. 
15)  Remove the chloroform layer and transfer it to the tube containing the 
chloroform layer from step 10.  
16)  Repeat steps 11-14 once more. You should have a tube with the combined 
chloroform layers from three total chloroform extractions. This will contain the 
total cellular lipids from each sample. 
17)  Add 500 µL KCL to the combined chloroform layers. 
18)  Centrifuge for 5 minutes at 4º C at maximum speed.  
19)  Remove the chloroform layer to a new tube. 
20)  Add 500 µL H2O to chloroform layer.  
21)  Centrifuge for 5 minutes at 4º C at maximum speed. 
22)  Remove the chloroform layer to a glass vial. 
23)  Dry samples under argon.  
24)  Pack samples in dry ice for shipping.  
Lipidomics data analysis
1) Use the data set from the KLRC in which Lipidomics data are reported as nMoles 
per 1x106 cells.  
2) Remove data points for samples with values below the limit of detection for the 
instrumentation (0.02 nMoles / 1x106 cells).  
3) Remove data points for which no signal was detected in both treatments. 
4) Add a pseudocount of 0.002 nMoles / 1x106 cells to all remaining data points to 
enable fold-change calculations.  
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5) Eliminate outliers from within each set of 5 data points using a Q test (Prism).  
6) Use a Student’s t-test and an FDR of 0.05 to identify lipids that change 
significantly. 
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